var title_f29_21_30032="Trucut spring loaded handle";
var content_f29_21_30032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Spring loaded handle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Picture of the handle for a spring-loaded trucut needle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30032=[""].join("\n");
var outline_f29_21_30032=null;
var title_f29_21_30033="Ultrasound of third extensor compartment wrist";
var content_f29_21_30033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Ultrasound of the third extensor compartment of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 271px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEPAk4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0yPT3J+9x9a0ILJUT/W/rXmQ8RX6TNEJsJnvVlvEDpHhpyD9aAO/vHSCM5fdWPHP9rcqXAHvXIf26z/euAF9zWdca2iPhJGLeoNAHpP2H5eJuBUltM0WV8xWA968pk1i4k4W4cD/eph1O4Vfknbd7tQB699ojY/NIAaczDb+7lH5149/beoRJhnLehq1Dq2oSKC7nb7GgD1FbZ7gYeX8qa2mvkAzYH1rzJtUv06TMvtupp1S+GS92w9t1AHqY0rLj9/kfWrn9ixyL/r8H2NeNtruoA4W4f65qSDXdR2km6fI/2qAPWm0bgo0ox65p0Hh+NPm87d7GvIJPEuok7fOkJ9cmtG11vU/JBeaQA+9AHqMuj5TKSBWHaqUuhTSLkz4I9686m1rUlxtmkI9zUT+LLuL5XlkyPegD0pvDPmKP3xDdzmnJ4b2OA825fc155a+J72b5kmcY9TUd5r99IxYXL5HoaAPTn8OwBeJTn61Ubw3lztuCB25rzU+I9QK7ftDk/Wo11vUI3/4+Jcd/moA9Rt/D0m757ngdBmpLjw2s/wDy2x+NecRa5dsOLp/++qbN4i1FPljuGP40Aegf8Ingf8fBFL/wjksYws5I+tedf8JTqwUL5zU9fEWpHBknbHsaAPSF0OSMDZOc+5pX0eRmGZ+O/Nebt4lvn4Wd8/WoRreou+WuWx/vUAelnw1Gx3NcnP1qOTw2uflu2/OvLZ9c1AzbftMoHrk1ah1e/wCB9rcj/eoA9Ej8PknEtwdo6c9at/2DGB+7nx+NeZ3Gs3y9JZT+NVv+EjvkOGmkH40AekXukSIhKzEj61kwW8pn2NIwHrXFz+Ib59qpMzZ7Zpz6zfyQ7WfY3bNAHpttpYTDGcn8auPp8cqcuM+teNNqetxZZLs7fTNPt/FmrRnbJKWoA9QlszBIcSEj60kVqJG5kNcNa+LsjE5O49zWhF4mgC585Q/1oA7QaQCNwnINEFsYGO+TP4159eeILiUEpdED2NZc/iG7yNszEfWgD1iSRdmPOAP1qi8eCWeXI+tcDb62CoaeQ7vrSza6o5WYt6DNAHbi181gUlYD0rVtIY9oRuSOOa8zi8TzK65yoz1rYt/F4QZLqTQB6AlrGwx9wVHPZW8SEs2a4ZPGc7khVVvxqC88SXtyNu3Yp9KAOruI1kXCvtHbmoVik2BUcE+pNcg1/KFy8pJHYGqd1rrxDarsr/WgDvH0mS4UF5yp9BTrTR/Kb5pSR9a86i8XahANpbevbmnp4sv2fcp/WgD1VLWJRh24q0ttZCLmRRn1NeP3HizVScAiqFxrl/dMPNmZfocUAexSWNqhJRhk+9Zk9pmQiKQDPvXma6nfIRsuXb8asS6lesAZZiv0NAHpEOmHblp/1qvcWxUELdAj6158+qzhObpyPZqSDVnYFd7k+pNAHe21uH3ebLgeual8mKMHbdrt9zXnNxrLplDK+B71Ct81whCyOD9aAO18X2sD+ENZmWcM6WkhGD/smvnJJH/vt+dei6xPdro96ombY0TBhnqMV5wnUYr1cv8AhZxYrdFqOR8j5mx9auRuwAy7fnVKKraKSRXopHIW42bP3m/OrkZk2ZDsPcGqsY5q9Cmceh61E9i47nWeEG33IIZtgYEAH2r1nSyyXRBzhkGTn9a8w8Cwbr2QMMD7w+teq2o/fR5GM8c/SvgsW71pep9phlakkT3fzq3nfd+7jPQetY9ymWLRZ67QAeK1p3AnBJxxyPf/AOvWfcrujOzCdGye1cxujhNalkN0iSsyuGwQD0rlNAD/AOmFixIkOOevNdfriK94POHzckHPWuZ8OIZYLkjqr8/WvZyr42eVmi91Cyq4b7zfjWfcK+D8x5962p0xxg59azpwSB0x0r6OLPAaMOYOCfmP51nTl+fmOfrWzdJ1OPwrKuVz71tEykjNkd/7zfnUVuzGY/M3T1qacepqG34lP0pslHpk5NxMzqNozUEyIflYsW9asswILEYOaniUPFwFzXz56pSgs4mA3M1OksY0P7s5NatqjoudgbHakbBl/ex7RQBlJaAt+9OPapPsEbsNhrX8tUyY03g05Y2JBaEr70AUvscZiA5+Wn21kX+4xCjtWqUVwAqHNWI7QnBXg0AZpsI3Xbk7vWqN1pEgx5asfc11ttaOHyUGatPbSt9+P5fagDjk0t/JAeMUxbLy2A2fhXarpbMevy+lX10iJ4/kQZ9TQBw0dnCGAZMfUVZMGzBTG2ukudN2DHlhsUiWqeVh4qAOeNr5q/Op9sVA2mwHIWPnuSK3/Lj3YVivoKfbws0mOD9aAOXGjRjJEm0egqW30cc7SWFdaum5bOBk1cttLWI7nOKAOEm0nMgULill0OMJgyfN6V3txZwuRhfm9RTF0yF25TmgDzxdIWNgGf8AKpRo6sQY3zXcXGhgOW4K+lVpbKG1G7H4UAcw1goUB1/KmrZx9HTj3rq7e0WfDcDNakGkWpXMgBPvQB5zPYIj7gDj2FVTp7XMh2ArivV30u3aLEaDH0rPOiQ7iwBB9qAOBbSyijKlmx1qvJZOibj8vtXfnTI9xVSwNN/sGI8kFqAOGgWSRMKuSPah7ITcGM7vpXdf2RtG2KIL70jaeYztK5J74oA4CLSgsmTwadNpzM3zyfSu5uNKyn7uMknvVFtNkiB3x4FAHKR6bvwvzEd6kn0uCNcMhya6CG0nRjldq9s1bSFSpEoU0AcQdGjZskNimzaFGFzGx+ldhNErkiOI7R3qA2aODjIPoaAOat9IXZ8xIpG0tQ3yAmuqt7EgHfUd1bkfKuPrQBzMukMyZb5RUcOkxg53kn0rpGiZF+YgionVQR8mPegDmrrTZoTlPmX0qm9rNIceWUNd9Db74gXwFprJGPljjyR0OKAONt7GeBdzE7u1aEEM8ygtJg9hXQSWgcbnX8KaIU8vAGMdKAMiW2aNRlsNVK4svtA+Y8+orpUhLDDpuX1qX7IqDIUYoA4xNMWJ8u+RT5rdUwEA5711Qsre4k2hDmrA8MmT5jhV9M0AcSunSu3BIHrV610CV23eYCO9dpbeH9o2FhitOHw8gX5WxQB5++nR27gHOfapHsUn4EbNXd3Gm2tun79Q3vUccltGMQRj8qAODk0QREPnHsarXGnFyvlnBz0Fekx6dBeuGcgeoq4dBs1GQgz9aAPKf7EbI80MffFXIdFWOPcAc16O2mooIVVA7ZqlcaaMHyyA1AHl3iHSymj38hZgEhY4P0ry6MV9A+LdKaPwtq8spyVtZCMf7prwBOK9XL/hZw4r4kTxr61ci7VWj6Yq1CPSvSOQuQD5hmtG2U7w3oapQjkY71p2/wAoBHXtWNR6G0Fqdz4BjWR5zgg/dzXohOZYXXqpH+FcR8PodtpI+Ou7kdM120Cl4AwwSo3D+or4DEa1H6n21BWpr0J5ciVS55DYIPaqF+5jicAbmHIHYirDuZP3ijknv6VBOdwIVRlTwfQ1iarY5PWkinkZlfACE4PBziuZ8FxeZplzIFIPnHPFdB4pZoNy8I2T268VR8C2QHh1Ju0rk/RvSvZyvRtnk5nskMuYBtyV2j6VjXKqCxHTtxXWXlt8rbsY6cVz13Htc/ka9+ErnhSRz90OOAKybhTnI+lbt5HgnpWRdDBGMV0xZjIxpx854qvAP3zfSrdyOT1zVaIATMParexn1PTpEUMwOSd3IqxHCZAoiwAKllYs7FEBJPar1jaAxiR8g+lfPnqkcAkA2Hr61dh06SZcuQRVm3dC2Fi6dzWtbTRqQqpg0AZ9vZxxJtJ5+lR3ULgfujkVr3lzDboWZRmsS4vlmclRke1AFy2s2kizKQo9qo3tzBZN+6k8xx2qpeXknkMsMhAxyKxVmBOGVtx7mgDo49cdgPkwPWtK31gOvLZI7VytvFM6kowIqawSVbnDkkE80AdJFrvlykMo21cg8RQgne4C1SksI5IAQAD61kX9lFEpAUk+tAG5deJrTfiP5s1mS65cSkiNf3frWCkUcLZlU49TU9xqVlHEFJAoA2IrpmXOBn3qUXSq6l5VQ+ma5U6vDMdsRIx0NV3imuZeHK+5oA7lvFMVo21sOB3FV5PGaTEjbsXtXJx6aVOWnX8TSyaWJDnzloA2ZPGjQSBThl9a1bbxxauqlxsNcFqWllI/kkVjWFO7QHYVJb1oA970/wAQWV5HzOm49qfLHbzjIcNz614Na38tsN2Tn61r2niW4hdS0jLH7GgD1a7jiVQI5NrfWqguJhwLjIHvWLp2ow38AZX3nHrUhi3NgMQT70AbX/CSG1ISQFvcVK/iqPb0XHvWJ9mAX95tYetRfYbK4fAchvQUAax1xZJNyOtC+ICjcupUdqrxeGIXjysrCqVxopt8qpLn19KAN5PElq/LybD71LH4jsS/zOGArgry3KnaAMjrWSjOZSF4IoA9d/4SKCTHlqNtPW8F0vyLXlVtdPDJmUsfYV0un6s0K7xJ8noaAO1ezWeDDYBrKn0yFCdzms2LxTbq+ZCfwq1/bun3DAtLjNADki8sgRkFfSrLWm9AVj5NRrrGlxnAdSalg120mnEaHAJ60AQtYkDG7bntVaXTd7f6wmuna1WVNyEH3qldIIziPrQBiNoxYYD59qs2+kBU/fAMKuiJwox1qvPcSwtgAtQAyaK2jj2tgLWVcMiHEJGPWodVvgr5ZT9KzJNehyEMJwKANgAsuXcbfanwJExxgn3rIGqWmMhvm9Kli1eNOwx7UAaN2xiAWNeDTYfs4AM0u3NVLjxBbpCWeEmuT1PxLFLIVjjKn60AegfbtMtQWjYM4qpL4oijz53yr2NeYza5NGSEXJ9ay7rUrmcnzidnpQB6pL4+0+JiOTj071Wk+JluCfKhfPvXkLgsxKbgajMjhwM4oA9KvPHLXTlnUj2FEHj1IkI8nOK81MpzyTjFRrIUb5CTmgD0ZviHIH/dxEHPFSzfEO+eMBfl+leZFmkf5uKcZZE4jyfegDurjxvqp585wPSrem+N51XdMWY15y01x1OTntT0upVHTn0oA9G1/wAaS3miX9rtG2aFkP4ivK4/erk1y0kbhjjIxiqiDpXrZd8LOHF7osxjkYHSrkXPFVIQauwjp6V6JyouwkLj2rTt+R74wKzolwqe9aEQAXnoOtYVNUzanuj03wEpTSBuIAVeR25rr7D5Io1Py4yMdTmuX8IRiPTs/eUgZ9q6i3fMjMAcEgqPSvz6o7ybPuKekEJcL5BByArjHrkioVUuioxAGeg61fuYleMkkkhvyqhFl7lVyRgdfepsOLOU8cQldnmkHg8n1qf4fQbvA9g+0N5m4g46YYg80eN186znWZSAsRy30rW+G9q3/Cs9Fd1w3ksQCexY4Netlztc8vMVpEzdQiCliASo/L8K5u/QbgQMeoFdpqsDK0gGfwH6VyOoR4bA+bPf+le7TZ4s0cxeKcnIrEuxgkgV0V8Mc8ccVhXa85P411wZzSMW5HbvVOD/AFxPtWhcrgnNVYsCU/StTPqfWmpeB9A03SNQu7dbvzILeSZd02RlVJ9K8jg1V5okkQg7hkivc/E8ufDGtDP/AC5Tf+gGvmrRYJXhjJJC4GK+fPUOrt9aCN+8A+lEviVELFExxTLDR9zB5WBBrVj0SwEgMgB9qAOZi1C51S6KhXK5rprVbOCACY4fvWzb2tnaJ/o6xK1U7yOCRjkIW9RQBmz3FnsOxMk+1Yskcs0wEEJCk+ldPax28XMqIR61qwz2YTfEEyO1AGXpthJBa5mixxVWQK84WIbSDVjUdbkkkMKKFWqqTRRL5hPNAGsJlghAdskDpWVe6pGT8wUAetYmravlyYs5FYN3cyXKFnbAHagDR1jVjKxSJAy+uKyVt5LlwHAwaryX6wR4ABIqpNqcj/6okGgDprPSFhwzMD9KnklKjajKO1YWkXNw4bzHdj6Zq0yKZN8r4HpmgCK7jlD7g5IznGatW955kYiRDu9TT4gpcYBYHvWtZ2cS/OMUAU7fSp5AWkY49Ky9TsRE580Zx6V1klysY+TJI7CsjWNRUwMDBzigDhr0qWwmeKgR227HIA96muXMkhAXaM1XmXao2sGNAFuzurm2lH2eUjHYGurt/EkzRKsilXHG6uOhhO3d901oW0nylXIJoA7i01GWdQTKpX0rRt3Tlt659Qa8+Uyg4hLZPp0q9DLNEvV93egD0a01KS3XBbcvrVldTSXiQjB9q4CzvZVA3liM966G2uQ0YKhTjtQB0DW1tLgqgamnQ7CdcBQreorNhuhIMJlGqQNJCd/n/hmgBbnwooy0cgY+hrHvND1MgrDFlR6V0NtqNwRvVCxHer39vNHFmWDFAHK6bokuP9LjwPetAaHExxCKnn8Rxy7gAqH3rL/t1hIQjD8KALU/hYhC4k59Koi0e14xz61DN4jvXYxohJ9ayr3WrpiY5WCGgDfh8Q3Gmk4uN4/uE1R1HxxeM/7tFUetcbf3Cc5kJasme6d+MkD1oA9H07xfOQWnmGK0ZfGcQj+6G9xXkvnLs2gnPrTkmdF2BSQe9AHqtvf22qtuf5TT5NCV28yH5hXn2nXtzbKCpBX3rstF8RykKky/TFAEd14clmkLK2zHrVFrL+zpN00qnHvXX3mr24tGZ3UHHrXl2t6il1cP8zYz1zQA/XdZMpKRnaOlc825m3BwT9afPJEEOW3Gs5ny2VBFAF8zuFw1NEgfjBxVTzCFGRnNOWeOMc5oAsOwbhflxUUsS43DqO9IZonXPAqvJKeitgUAO81TwRSeagbG3BpgbIzsFMZi3IXGKAJ/MGclTxS+cD975feqpnwMHgmopJgwwevqKANWGWNshu3eopyobO78qz/NG0Dn6il3ovIOTQBPIY2Utg7sUxO1RedngDg1NHzXrZd8L9ThxXxIsxDpVyHFVIquQjoc16Jyouw/d6VdLmOF3XBIx1+tU4ehxVuZR9ikP0/mK4cdJww9SUd0n+R6uTUoVsfQp1FeLnFNeTkjYsfG+pWVv5MMFmU/2kbP/oVXoviVrEZUrbWHy9jG/P8A49XEUV+ce0k+p/QH9i4C1vZI7uT4n6zIXJtdOG7GcRv/APF1CPiPq4l8wW2nhv8Arm//AMVXFUUe0l3D+xMB/wA+kdTrHjfU9VtpobiG0VZQVYxowIz6ZY17p4DiR/hjofB4tQFJbAJBIr5ir6h+E5M/w2sIymWgMsGAMnhz/jXsZVUbck32PguOMDh8IqDoQUb817f9umXqsZjR1LDnHI5H/wCquI1aLbMx4B6kA9DXpevwRIS/HTnB4/GvNtcUNcNjg9a+ios/Opo5e9UYIyPwrCulJ+neuivh97Axj8K5+94Bx1NdsDmkYt51PU1SjH74j27VeuuTz3qlEP3x+lbGTPr3xBNnQNVB6G1l/wDQTXzwLxoooxFwuB0r3LXZt2iamCSAbaUf+OmvB4FTy1BPGBzXgHpnT6dfSSQKPNA4qy106ffm4rjldYZMpcfgDU1xqiFdshJ9xQBu3N8gbm5bj3qrJqcg+WKU4PcmsF7yOQBQM+9QOJAwySE9qAOhS4nZtpnOPrVyEXRXCz4H1rmo5QPuMSfWrCXrKChk2++aAN0QzO2ZJsGpzGhiIaYgj1rnUvHjbKy7vrUV1qBOSr5PpQBavWWF2O/cPpWDeXm5iNxVfarBla4Hyt83pV3TNNm1KVbaG0kuLh87I4ULu2Bk4A56A0AYIiJ+ZQXFPjkUcEAGt670nVNLuoLa80q+t2uCVhWa3dDIRjIXI+bqOnqKbdeGtZjv4beTRNSS4nz5UTWrhpMDJ2jGTgAnj0oAqWV8tucbce+a14rWG/j3iQg1Tbw1qIv47KbTL+K8kGUge3dZGHspGT0NbVrp82gssOs2l1ZmTlRPE0ZYeoyBQA20hMf7tXDVoLIIwIyn4mopZ7HObR8N61janezICQ4Kj0oA2bzULaAbdwD1yGvamZcLHIOvUVWvrzzVyME+9YMivJPhvXtQBdJ3EbpCSewpSo6hTmoArRjCKSfU1Yt97Y6lvSgCSNJ5iFY7V9auC3SFOXBal+baFKhRVG6kkQkcFaANaC/EPykDNLLfmR8KcVgrdgDAXJ96dBcZYkYB96AN5bx0GS24e1TRa6Y2AiBB6VzzzSKcnAB96esyYyQS30oA7az1iRucqTVuO9kllzKG21wEE1xHKHAKrmuittTlMY5BI9qAO0tNQZVwh2gdjV43CzRHeVb2rjI9YjKbG+8e4FTwajAnJkbFAEeuQzNMTFE23/ZFVIbW6QK8cbZ960xrsYm2oQUFakeq2ksPGA1AGTDfSphZoMN/exWJ4jAk+eM/N3roXgnuy3kgAZpp8K3V3CzS4Ax2oA85kYYOcswqsHJJ3MQfStvVvD17ZTsI0LD25rFltblMiSNgfpQBJGwwAAC1K8rxMCTkelV0QqeGKnvmlmLFfvA0AX4b4Om0KRWjaXssYG1wR/KsK2Wfso21dgg82QKGKnuKALupXzyJsDMw9AaxpJDyGzW2dHdFLiT8zVKbyoRmYqxoAzZIwqZPQ1D/AA/L92p766jZOOBWb5jM3ygkUASTThSAoyKhklboVBzVqOEtgsABSyKpHygAigCihznOQa1/CF7a6f4o0251O2hurBJl+0RTIHVozw3B74JI9Dg1Q2RtwH60x0jU4ZiD2oA9Ks/B8dnPPoOoSQx3N/qklrFdP5eVtLWMzSzIzYC7x5ShsgfMcnqKpwaLpBYvpeqTWs0mmanNNaWWuW95Kiww7l3S2/ASTOCpAPysMnrXMXniPV77U9Ovr3VJ5rnT4Ft7Riqr5SL0HAG7PctknoeKWTxHrMzlXvooYxbz2yx21nbwIqTLskwkcarkqANxBI7GgDb1Pw3ocdpdW9uuqf2hbaHBqz3ElxGYi7xRyNGIwm7GHOG3ccDB61we0Acqa2LnVdQd7mT7cxe4s009zsT/AFCoqBB8v91FGevvWfiQJ8vI96AIAygDcOPaiRkK5XipwqyDDjBHpTZERF4UmgCCIjcOeauRdapKwEigL3q7H6162XfCzhxfxIsoKuw/SqcQ5GKuQ9a9E5UXoOa1LeNZtkbruVmAIzjNZkA5HFbOlAm8gA/viuLGW9jO/ZnZg5SjWhKDs01ZrdancWPg7R5FVpLPcGH/AD1fg/n3rZs/AnhyaMl7Dnt+/k/+Kq7puBaKP4q2tPKiUL93cSDn6V8E4RvsfoCzPGct/bS/8Cf+ZzqeA/DXmc6b8vvPJx/49VPUPBPh2GLCaeVYthW86Tn82rtIU/dy565IU+9Ur1vNi2uA2Oo/rQoR7B/aWM/5/S/8Cf8AmeZyeG9Mha4MloCsXXErf416F8Hr2OPTrjTpHxK0z3UYPdWPb6Vy1/bLHqTxAny5FwPfPrUWnXz6BqdnfjhbZ/mA7xnhh+VduFkqctFuedmNWti4L2s3K2123+Z6XrERKSAj72fvjA+grzrWlQMOhCjt3Neka3KLiISxuJIH5Qr0IPIJ9a8+1n/WcjjPBr6Ciz5iocjf/d6HB5A9K52+zyOmK6XUVxng4Brmr0ZzzXdTOaZi3PAz1qlH/rj9KvXfWqMX+tP0NbmJ9Ka7cAaLqZJ4FtL/AOgmvn2S9do1VD8pAr2jXbgNo2pgng20o/8AHTXhFvEzqu08ADFeAemXgvlqH3EsfWpEuUHBBY/SmWsW/wD1j4xVnyowCGIA9aAEjvFDY8sVZe5SReCRUItkKdfl9aaFjj+QMMepoAY0nlnKvVOeUPKNpPvVqdMKShDetVSytkbcEUAa+nPGfkcjpTr1Gj+ZACvpWWmyPDBufrTpdQZlwT+VADlnIkBC7TXY/DmT7T4thh8uWffa3a+VEcO+baX5V4PJ6Dg/Q1woeNwQGO41GlmzllkKujAhlbkEehoA7zwv4dl0ae8Fj4bvPDOqXmlXEFjcXt0PNaY7OEY28W1tm8ZyfmZela/gjwnL4d1GN9Wtbm0h+zXrJbSOYXlb7LJvYK3U7c/OVP415zp9vp+nXAkitYI3I2kxxgEj0OK6KxsdDlt5Wt7CzieRSsgWFV3g9QcDkGgD0LwbYRve+D5dIiWHQbWymhW0jk8yRbmVC8iswVQeEXaQgzlzjORXNX2ipZeEPC9ld2E/h5PtMqQabNL5s05eEO0rkxRldvlbSAmNzgk5rm3gjd0ElnHIkeQm9AwUEYOM9OOKsaauk2ZZrexs7OQjaXhhVCR6ZAoA0HsLO0XmYE/WsS6IeRkiGVPemX4Nzc7bdywNdHo2jvDAHlAk9qAMix8IyXmGLYDVs2/gGC3YSSykn0NX2upbVtsP7sehqG81uRIMysWftg0ATv4YsyhGBmsHU9JSzb91tK1Sn1+5Z/vNj2qpLrB3YkY8+poAstZJMvDEGsPULRreTCtkGtRtSTy8Fh9RWHqN35jHaSRQBVkyr4AGaeionzP1PpVJjKXygOPepVBDDzWJ9hQBfiEcrjGatwxEP90EUWsKNDmMYNNl+0DgKcetAG5bEFQrRDbRJ5CcBcCq11p99pVukupXelWqvbrdLFPqtskrRsu5WEZk3nI6DGT6Vo3Oh6raLMbiK2YwCJp44ruGSWES48syIrFkDblwWA6igDPnZI0BTikH+kQnaQTTNYgNle3FleER3NtI0UsYYNtdTgjIJHBqlBMoztOygBWhaNid5U05LiaA5zuX1pjBpMs7Bl7c0sKBkbP3aANyx8Ry2pXLgr6V1lr4sgltxGJAGPFeVzo27AXaKWNzDjblW9aAPVPLkuTvDqc9KrXOlFhllQt9K46yvrqOPKTH6Zrb0vXGZhFOxB9TQAy88MxTtuETBj6VnXHheaH5o4GYeuK7ZZgFVxMNtWk1y1SPynO9iMZAoA8yeyaJtrDaR1qBpUgf5AdwruNQtrWWVpIyMnnFc5e2bl2McQYUAYc17Mxy24LWVfMsp+UMD3rp4rOV22MgB963NP8ADqTR5coT9KAPJZTtbbktVuEBPmIxkV6Fd+B4mkZzIqn0FUV8L+WxwQ6CgDjmmXOEzk+tMcndzk57iulv9A2/NEMEdqzxpFxMCqfKaAMhIMHcHA+tRuwL4I3e9ac+hXUQyVYn2qBNGupDgqwP0oAoTZB+UjFIqEAsxzV9tFvUfaY2Oe+KWTw/qKfdjJBoAz4VZmJGalw/Jc8elWjZahCuxoGBPfFRf2fe71Z4mwT6UAQKMqScqKMjGd/51ems50UbkO30xWZc+YGwIjge1AEbDMyso4zV6OszzGMsYCEDPNaSHFetl3ws4cVui3F196uQ8mqUXX3q9CTkYr0WcqL1v1Brd0OPfeKe6AsKwYGyRXT+FkL3M4XqIv6152Yy5cPNnfgI81eKPTNNY7ImPOFAOK3rUiSVVJA45+tYeiYe3UYxlQv41tQHbdR7eDjBr4jqfX/ZLcZAgkxklWJqjcnHzgde39avW4eOGZDktuJNUbpSInJ3deB3FIqJzWqYXULaQD5SSAT0YHtWJq1rHMXTcFJ6Ejn6V0d7B5kamTmME/h71j60PKWN2YhGHLbeR71rBkvsbvgm7+0+Fo4Lh/3tixtmx37qfyrM1Vf3kgOfvZGazfBVwItYvbQSF0uUEy88bl4P6Vpa3JvkbOeDzX0WFlzRTPm8VHkm0clqJPzZ6g9q5y94JroNQYjdzxXO3vANenA4JGPc45zVOLBmPParVyeSe1U4T++OPStzHqex6vcA6Zfg9DDJ/wCgmvI45URFKnHHevQ9TuAbK8GesTj9DXmm9V2qy5WvAPTLjXZK/Lge9TQJLPgq4NUfJRiCPu1c06b7PJhQKALhS4T5XbC1DNGT9z5z61ozzNNCQQB71TAS0/ebsj0oAhW4ONjR4asy+SRX3DIq3dagkrfJ8pHes6+vgIyjksT6UAR+YwHD/nVq05b7w57VjRHeTnmrcMjR4O3kdKAOpsdFe4XecDPTFSy6DdAZjJJqhp/iF4UCOMGuhstcSQAPIBQBhS6XdxKWZckVLps8scwBjyR2rrxcwTRHeykVgXrQQylrc/NQBqvcTPDxFs4rm50uri4ICFhnsK1rSK+vgFD4Wuj0+z+yQnzGQv6mgCnoujYgDzJsbGeauS6xHp+6N23Y6YrK1rV5oQYkfPuK427ubgyEls59aAN7XPEDzNsjwAfQ81lvqzRw4c7ifWsSaCR/mV8GoTDM5wx/GgC7JezSMSuAPSqstxIzYJBNN8sKCGJqEJweeKALAncrtp3n4XaQR71nRkpKQpJFT7S7ZL0AWkdTxk1bghC/Mx3fWq8MTyHCYratdGkkhDF+aAJbbKxZC5+lPkmkYEFcelQhZYH8vkCrXlDZvkY5FAG542vIJYoZLU+Dm8vRrSOS4utUAuldbcBgIhdJ8y9l8s5PY07xL4ltP+Eo1m30KGJ2vlsLe81Nr5ZU2JBbM6xRqgCn92qks7YKtwOg5xyJUIVQQKqRwF3IxgUAbvjWC3m8V67ex6pos8FzqU8kIt9UtppHVnJB8tHLdPUcd6wpLRFbhifpUn2VQ4BY1YPlW5BYk0AVQ6RHlGI9KnF7F5RVYyp96k/tSyUEFfm9xVYzW877j07AUAMWM3AyW2+gqRbaUJho9wqSJIM5DEVt2F0qKFdAw9aAMGFHEqqwKrXR2drDKgORkVLM1tKpOwZrPhgzKWViqj3oA3xKLaMI6l07Ckklt2jzHEVNV7SY8gsGA9ajv9RSE7SBgjtQAspd48AjPrWLcXdzZsSG3e1JPegKShbmqBLyHJJJNAEsutS7TvTafWptN1edCWSbbntmse8tpJDw3y1HFa+XyGJoA6salLMS3mnI68086nLt2pzWJZ2jyEdQDWxbWTRkfOKAGySPIA0gOaYkzLKNiGtP7AGwTId3aqV0k1s5yMr60AWWujJEAUANOtpgCA0YJ+lZZ3/eZwFp3CpuEhz2oA6B3UAEIp9qct9sxmFSK5/T3uJnI5x6mtVLBn/5anf9aALTXiytjyE/EU37TCuRLAuPpTV0ic8mUD8aZd6TMyfu5cmgCOY2N0fLEYBPtVGXTrCGTBC8019MvIc7Qc+tULm2uFkxI3PrQBf1bw9ZnQ7u7jRQ0cTOMeoFedx4yK7C6uLy20y8iZ98bxMpGegxXGpzXq5f8LOHFbotxHFXIj0qjEauQ9vevROVGjb8muy8ExnfPJ2ZcVxlv94HvXe+DQEhIPXbn8zXi51O1FR7s9nKIXquXZHcaL8kasOQDk1sOc3MTq2VZsjHesjTFWKMAjnGPzrUvSFgglXsccV8ifTNdDRbcsjAFSO4z1qnOm2WTL5BA259O9WdwLZXocEYqvLsJcMRkDAPpTZUNjGuDLbjpyflUdR/+qs7Xstp6mVDt3YGO1bF8ARGCOBkg+orM15SbdPKbLMMHHSqiQ9zj4pTpus2N3yEEojYj+6wxit/WG+Z1HY1zHiESixkKr8yjf17g1rXM5mtopWP34w5x7ivdy2V4tHiZlG00+5iagTls4rnb1sjJ/Wt6+PzNkcVz98eG4r24HjyMm5Y5qpDxKeexq1cdeetVYT++IxjitjE7O/uN1vcrnqjD9K4tIWK5yQK3Z5yxkUHk5FV0iEajzSo9q8A9MyslPvbjirsM8QXleamlaAqfums0OdxWPoe1AGj54YHaxA9KZdPH5OQ2DTLewndgSCtXJLJSvz4JHWgDnSzO5AUt6YqtKsiN86HPvXS/urdTtQA1k3TPM5I49hQBQIOARhTUqBuCZKlSBAfnyTU8dsZSM4A7UAQooZSW6+tWraM8FdxrX0/RI5lG59tWf7JEEoWJ9/sKAK1osjMoLsBW9YWsecld/uataZpMkgG+MgepFa62UNmuXINAGcNQNr8qRYWqF1cTXTFg21fQGrGqXkbKVjX8awmkuIwWXvQBHepJuI3FV9TWbNsAHz5xS311cS5Vm21kNPIjbWYYoAuy3EKrjv6VWW625J6VSmDhtwOaqyO5bJPyigDSlvEYfdqk0g3ZR+KrFy2dp2iowQG5ORQBd+0jJA6+tTW8hDD5M+9UYgoYnOB2q5C7EHYeaAOgtGGwHhWrobG3up4l8liQfSuLs2cNhwc12XhzWHtXWNwCtABdaXfI3IPPfFQtpt0PvuT7V6dZS2d5ApbAY1oWui29w/zBfagDx7iDiSM5qKaZWX5UKn1r2PUPBNtcHcmN1ZF54FUfwnPtQB5fGQR8z08SRYxJlh613reBSSS/wAi+lQSeDIFBw5GPWgDz25jty2UXdSQKN3yjae2a70aFZQDawDMO9ULzSYiTtAAHpQBzhJ43EZ9qtWr/NjJ2ipJba3jOM800R+UQR0oAvJEknKsavW8EIXEj81RsEErEhsVqfZiq4XkdzQBBdCOKP8AdOMd6w7q5RW6bvermqGJBsU/NWFcbCCC3zUASSyuVyoBFTWaNKfmyPeoLLAwrjk1swW5A+XigCNrMHkHP1pEtlbaGXn2q5EAr4ZTmriKhYAAZ70ANtLUiPoFqaOzJbKNz6VMuzIUk0SLMp/cDHvQBMlo6qWZufQVR1O5RYSrxk471YD3MaFpnGB1FYOrauSrII93vigDKnuF3tgkL2FPs75GIVlz9ayJXeYkIpB9qu6cwjGJl5oA7mya3NuNoGfQUy5nESEKjbvWqmj3duuFUZY1tSfNgPH8p9aAM62upcBndm9q14ZvOTdtZSOabbW0EUwbGc9qt3DuflhTrQBmXM8zEgdKoahcW6QESqN9bkOlyO5aVtuayfEmmQCM5kO7HagDitRmV7W4xJkFDxXNR11dzpwi066k3A4jbj8K5NOterl/ws4sVui3Hg1ai4xVSM8CrUdeicqL9v1r0XwjGd0Iyfu/5FedW5+Ye5r1PwzGFmXA6IPzr57PJaQXr+h7+Sx+OXp+p1YBUArjIA4qw7s1hIhI3D5hUcQ+aMDPK4p8o2krjIx2r5g+gWpdgmDQxZzvZMqfWnIA8o6KRx65NUbMh7IEg74mKg+1aMKZ/egAtxVPUI6Io6iDJqZjGMInIH9Kz9Ut82CsFwQcHHYetXyA2o3LluOmKhu0L2EiDJBBbOarqR0OC1ONhHMEJ6Yw3oaqWcpfS4QSd8eYz9RXQX8Ie2VVGWUdDXMR5t7m6iYnD4mXjseD/KvUyydpuPc87NKd4KXYrXhAyAetc/ddT81bF442degrDnYnPIFfRwPnZMzrk8VVh/1pz6VPcHPFVoT+9OPStTItSXO2Rj6EmoJ0nu8yB8L6VQ8/Nzj1fH61rJImCrZX2rwT0yjHHLEcONwrT06dI5lMsaEZqLaX4XOKQ6a7fMrEfjQB0N/qCvAfsyc46isX7VMR8/Az1ojea3ATZmnkCU/Mu00AP2xuoPLGqtyDGDtQYrX07TZrtwsQwo9K6aw8ML964GfY0AcBBDJOu5U/MVo22ltPgHKsa9Aj0e1i+4q/QVbi05R/ywX60AcrpXhq7kIzKAtdbY+Gks8SlgzD1q+slpp1vm4cR1yXiHxjwYrV/l6ZFAGzr+rCztzGu0HHUVw93qkkuSJT9KzZryW+c75D+JqrPFs5RufrQBpLqWxvmUPVPUtQEg+X5D9ayJppEbkgA+lRttPOCfegBzTuxODuqGQIRuk4JpVHmHhduO9JO8OzEhBPtQBTnXP+rk4qt8/QDdT5JIlJANMRwGO05FADTuxhlwaUKCOo4pHd2OOMVFI4U4JoAn3kEbwMVPbYZuGwKo7xJgdqVVcPkdKAOithjGXzWjbTr5mVOCKwbG4ITay7jV5JFIy459BQB1NjrT2kozJurqLXxZL8piyD615vbyxHjbz71ejmZAAvGenNAHqlr4vuGwGfGO9akfjEbQpXzD614/DLMrZLcHtmpF1RoJM+Zg0AeqXfiNpOQCq1myazFJkNIQa4Y63cOPlKsKWPVAxw6c+tAHTXN2nmHj5T3FU7m+WKI7BurN88SIdj/gTVFnIkwZBk9qAHPKzzb9n4VaM4cKjJgd81Wy456UjOxU+YR+FAFqPy4ZMlyM+lXlnZkwsvy+mawI97MRkbfftV+xt42bazkt7UAU9UhYyEgkZ71l7ghJY5xXRanA8UB2jK+9cw+0sd/HsKALSXSghttaMOoecoVHw1YHnqoKhDiovOSP5kYqaAOoRrsvy3HrVuNzFhpHJPauYj1Kcpw3AqVNTlfAA59TQB0zXyk/KSG96kjuJX6TYrlZr1o+XG41VGqyCQ+XwPegDspbx4sh23isye7Vm4i4PWsFtQmlbDc59KsRzuowOQaAL7tAOVwp9qaGMjAKmffFZ7XKpJll/CrcF8B/BwaAOh0X7JFMDI+HrsrOOK4I+cFe1edWpDrujXJ966vw28jEBiFoA6Zre36KpLD0p6RyJ0jwPU1Vka4imBQhqjnu5nyGkK0AQ6jqotiyyYJ7AVy1xczajcbQdq+9Taxcwxykkh3+tU4bpSdzrg9sUAWNX05bfQb59+T5LH9K8xQ16Pq6XE2iXsgDeUsLHJPtXmyV6mA+FnFit0WozVqI9qpxHmrcZr0TlNOwBe4hHq4r17w8oQs/8AtCvJ9CTzNStkH97NewaRHtt+R1Oa+YzuX7yK8v1PpMnjalJ+Z0UagSJg96fMuGOPvkHFMjPAIPJx+FOuyNoIPOK8Bo9qJXsmKxXEeQcNnr1rSjYtb5PpjIrLhjVriY7Tny8fQ1oWrsbaPavHTFNB3IACLi4wfmzxUQ5t2UnGARUikfabgsOn86z7SUSx8HJYn2xVIVroo30am3iKjDDg4rkNeiaBoLkHhWMbf7p/+vXdSyII9hXjoaw9Z08T2E0Td1I/wrahU9lNS7EV6ftaTicBfOfmA/OsW4PGB1rRuncbklGHQ7WHofWsi5b24Br7Km01dHx1ROLsypO3B9TVaEjzT34p856/1qO3/wBceO1WzIxoZgdQiBPBmGfzrtNtpu65bPevOI5Sb9AvUyjH511lusyzbnBPNeEema9yAo/dgk9sUiNLtDNkD0qINJIwVW/Ct7SdGvr1gGQhPU0AUomeUfKmPc1padZCZv3uCPauttfDtpHBtlbnvzVDUYYdMUvajeR2oAfYJHZtlPkX3p99rrR/KhV1rj9V1m5mByu0Vmw3UkmTux70Adc+vRKclmVqk/4SDMWRcHPbmuDvbpM/M4Le1VC7H5kbPtmgDoNX1mW7ZlkmYqD3NY5cHlSCazpTIxIZlANRpI0L8DIoA1QSuctgmq1xJt/5bGoZL1WXBHNVS6s2dhoAmlcMMhicetRi7JG3bwKRnKjlRioTKjAkqQB2oAnnuSY/lOPpXU/FWztbT/hDFtbeC3E/hu0uJvKjCeZIzyhnbA5Y4HJ54rifPTOAhxXqviA+AvFum+GZdQ8dvo95YaNb6fNajRLm5wyF2J3rgfx44z060AaXw+8YW2rWniNL3wX4HcaPoFzqEDLo43ySxBdvmEsdwOTnGCfUV5b4v8UTeJ7i1kbRdA0hYFZdmj2X2ZZMkHL/ADNkjHH1NbXhDUtE8Nah47gXV3vLC70C80+wujaSRm5lcJsHl4LJnB+9wMcmuCBYcFqALMbZBBbJqOVefWoi6x8gZNRGTc2RkGgCYMR0qQSEkYY1VLOBywpVYdS3NAGklxgALwa07HoSTk1gCTJ61at7iTGA2BQBuqNxJWQAipoXkBwW3D1rAaVwc7s/SrVncH8KAOgRgDlpKfJHEyZ3AmsO5bgMpOKSGR5DgOVoA2IisR4LCpkk2ZO9eayC8wH3gyio2vT0Cc0AbhuQ/Ak2momuVVh8xJHU1iPLKeduM05ZJRjODQB1EN8gT7xJ96lQtKOAKyLTmP5hk+wq9bCRV4JAoAm3Oj7XUAe1WWuTbpmMbfeoCQg3udxHrVC8vJJcqmAvpQBLd6tLMChJI9RWLdOxb5SadJx1OPpUEqO3zIw4oAckjhdjZB9aWFd7/Oc46U2IsEO9hmmCUgY8s/UUATiOYSfd+X2qxHG6cqfwqOC8LYRwQKtIIgOSaAI5HUDn5m9K3/BHh3TfEmsx6fqesf2VJcMkVsRZvcebKzABflI29fvHisiOOGTJj6j1roPh4oX4ieGh/wBRGD/0YKAL3/CC6PL8S7fwhY+KnlkYywz3J0141hnTP7r5mAbOOqkiuRn0+e1uJoLgOs8MjQyKeqspIYfgQa6vW2lt/izr95blluLbWppYmHZllJH6iu48Z6HDeeP4ZrKAND4hSK8tx1Ad8K6/gw3H/foA841fwmumeGtB1Se6ka91h5TDZiL7sUfBkZt2epUAbf4hzVG2sZgQuzA9xXovje5i1Hx9qMdmB9h0aKPRrUADA8sZlP13tt/7Z1lSWykAs21qAKNppjRxb2bAxnFSi9t4Pult471bVJiu0sNtVLm03MRGgyO5oAtReJ0iiKhWd/esjVNbvbosIwIkNOltG242DPqKx7oy2zkSLuWgCGGznubn55ScnqTXWWWnNbxAunnH2rmIrwkDYhA9q07TXruFlWKMke9AHR6zHMfCmokx7EFu/wDKvGk6e9esa5rs9x4ZvYpUCl4XB/KvJkr1MB8LOLFbosxnpVpDVRDViNhXoHKdP4PTzNXUnkIhNevWgMcMSnglc15T4CK/2hcBuvl8V6tdfu4oHxjHyn8RXyWcO+Ia9D6rKlbD/eacLAwKWPTrip5nDoOBgDnFUbRw8Loccjn1qZ/kTuAa8dnpwZJGwWTrgtkVbteUCkjA6VmQncAfQ9TVqOTyonYtzg7R6mqQ2iS3I3XDHGTnGKy7OPy1kDdcdanEpQMvqKikOQxPGU/UUxx6lZhhyX5Gc1YESy2uMEkjP1rO1af7Pbwt1L/rUWjap5sxVuDjG0+lXbS5HN0OK8c6abe6N3GvyHhwP51xVwwBIFe2eIbOK8tX2gbWUjFeO+INNfSroQSNvUjKtj9K9/KsVdexlv0PBzPDWftY/MxZDySeRUducynntSyt2qO2b96fpXsM8ZHI2kNydVg/cTY89edh/vV6daWtzNKEC4yeuK2LHRCBmaYg56ZrW3W9hB+8KnHpXhnpFXStIW2kDyqG9Sa6OLVIrf5d6BR2ri9R124ZGEAwnY1hHUZpM+YTQB3eq64pf93IDj3rnr/WZjk7lArn5H3gnzOvvVS63bcKxJ+tAFy7vvtDfNhRVO4ZGX5ZdtVApGS+Til3Jt3EDNAEEkbclWyPU1CZmQY3Y/GppWLrgDA9qz7hQvBNAFt5wI8ryageaQjOfwqruA7kU83ACn5efWgCeOfGSevenLcMW+9gVQD/ADAnpUivuPK8UAXJGJP3yc1Eytn5eBUQfYTyMUx2c/dbigCVnfoMZqJgx60kTc4c0SsAeM4oADwMEkmo8hT3JoDZHHX3oK7V3E5NACFs8kYpjuOg4PvSCTsy01sPz0oAdkdSRmkUHfkc00EIOBup4cFc4waAJST/AHacrnjtTIwSfvCrCIR/DmgB0cy5wauW5RjwTVUW7lsgACrMcLKuc4oAtBgrYZ+PSpVm44ClaorIG4ZcmlKgnCsV9qALjyxryCc+lRpKhfc35CqW1w2N3HrUhkRcAg5oAvTS7kHb0p8U6Ko+6W96y5ZZSPlU7aiTOQSTmgDo7fVWjOPLGKmfVGc4HDdgK5wu+RkGr9qwcqCpDetAF97i4kGJFO2iKGVx3C0+IyBguCV+la1vbrKAScCgDFNhO2fKbPsagfT7mNT5hwv1rr7W2CPwN1WrzSluYtxyuBQBwKQKQfnY4p8cxHypz9av31p5EjLGcCs0AFyrDDeooAnfft3FAadFM2PnIxUex0X5Xz7U+NgVw8dAEyktIAr8H0rs/htNo2n+JrTU/Eeqvp1vYSx3Ee2zluTMysDsxGCV6dcGuGjJDfKCRVqa/MUOClAHonibXfDp8RahdaDqMupLfTy3jySWEtsIS7kiP94AWIz1ArqPDfxF8O6f4YtrnWJZn1zRDctpkKW8kvn+ZHkISqkL84XliAMDmvBob1WciUEZq/aCMtu38UAd74eeJdLgSW4DXJy8znq8jEs7fixJrRnjLDKEOK5Gwu7NMKck+tbEN+pdQjlVoAuYl342kVO1gfK3vIwpPtCEAh93sKsJcecvlspC+9AFO3hBYjzPl9TWT4h08QjzI5g3+ya1rvT5CC0DnjsKyr2ByhEvB9zQBkWG1yRJ29K0op4YnGUOayVKxMwdsYpyXyq2FXf9aAN3VZrJ9Bv2Zj5pgYKPfFeYr1Fddqdy8mn3AMe0GM8/hXHqcV6eB+FnHid0WUIqdD0qslTx16ByHTeDpCmrDB6rj9a9k1Bd9mUT/WbAy/Udq8T8JPt1uDPQ8H869sv4s2xO7Y6dGHcV8rnCtiPkj6nKNaFvNlXQ7sTDPRiuD9a1WcyKcE56GuG0K+8nUJbaRssG3r67ScZ/OuzjfcgOepya8icbM9KD1sWEQCLAPy55piyk6hCjAkMSMHp7VPafvLcsfu5OCO9NUndlMbwRg1KN3vYCpDMG9cZqu48wmME46Cku5tm8lssW6dhTtPbdId3RhVWBrldzJ8RJul06MHgyFf0rEm1HTbi8aDT5T9st+rHhZD3UHvitXxy0kOmtPDnzIVZ1I6jtXlIfykj8olSACGzz9a9PBYRYiLu7WPJxmLeHkrK9z1+0uRe2HB7dO9cn420r7bBJ5QzIjZQ/h0qp4R12T7Y0MuPMxu9Aw7/jXUs6Xju0Z+UuT+lYcs8NUs9GjdyhXp3WqZ4VcBkZlcFWXgg9qZbH96fpXbeNNDV0lubZcTIckD+IVw1qf3p/3a+kw2JWIhzLfqfN4nDPDz5Xs9jqdQ1aWaZ/KJABPSs+XUZCQrkk+9Y0l/5dzIAeMmqk+onzCcH615p0HVrqkQi2yJis25vlkb5cAViLeM4zkn2qNpsHheDQBoz3UYGEbmq5udw4Y5qBHBP3BTZpkBwoFAErTtyHJqPeQCQ9QtM5/hFNZxjJXmgCT7TJnpUM8rtxtGKiklcjCJioQWydxNAEpyF680wMD97NNL4PQk05cEUAKWQc9RSg7h8uacVQJk4zUZYE7ScUABHYnJoPHQ4pGGeFINQyEjhgSKALaAFRnn6U2fJ6nFVkd04U8UhLZ3NyaAHDavUnNPVz65BqIYkHPBFG49AMj1oAkfAB5yTTQOOTio2OCMjNJITkYFADncE4WnoXweBTYyGOGGDUoVM9T9KACN8n7vNaEMgUDJ5qtGihcipwy7csBmgCf7SxYbeRUyeZIMrwKph93CDFTxzFBgkUATeW65ORmmnfgk4o3sQSGBPpU1ukcrgytigCvHFLL95cKO9Wo7UBfnYVed4YUAj+YVVLc7yOPSgBjEKhXjFVt6/wgZ9KkluFwQACKjjdcZ2gUASIGI5xmrtoVjwTnn2qgzArlQRz1q9b3ACKgwTQB0VjJEyjIx+FaSPbqOVNY9q6mMBjg1oQXUEa4k+agC3CT5mYm+U1aaeRFwZMiqCXltn5YyKuW/ly/MUYigDL1FUkJyufQ1kTaY+0yKQfauzezjuB8kZBpE0MkjcpVaAPOGWUTbSNpq1GkpHLDFemz+ENPuLbewYOB1FcdqegyW87CEkRjpmgDJjfaeSMCq1y/wA2fv8AtUs9tcIcckVG0MirgEk0AVziRhmPk9KshJ0XIj+WozG45ZguKeZZ1XHmDHrQBJDdShh+7xit2zklnVQxCisKHzByzA1bjLkZDFiOwoA7exWKGIFmya0rAxO/7xjj3rhrCecMGeTAHY10dnrMDAK+GYUAdOz/AClYcfWuT122uGkaRmwPrW9DrNgEwykPWFq1wbyVjCG2+lAHPlImPz7mak3eXxEuPrVlo9jfMpz34oePB3KARigCC9n36XcAkZ8s/wAq5BTXW3skZ066AUA+W38q5BDXpYH4WceJ3RYQ8elTqarIamUivQTOU6DwmN2u2q5717rqEW6zV0ySUHA6V4X4LG7xBb8/dya97Y7bDAIIK4r5jOP469F+p9Pk+lC/m/0PFry5ex8VStuJAKBvp6V6lpc4mtA4OcDg15B4mb/ipL5RkYYAflXoPgq7+0aIuX5yIzWeNopUKVVdrf5F4KtfEVKb73OytpmSzjOPvdD2quZjHJlucn8qsJgW0cYxxjArKmbLsDnAya8mx7D0ZZuSJWHQlsY+lMe4CXkcSnBFOhXeLYrgjpj0rA1K4KXl3MMkxy4x7VaVyKrtI6DX4kuoMcFdm0/jXiFwjQSywP8Aehcxn8DxXuFuwnscgglgCPevIvHNobXX5WA+Scbh9R1r1cqq8tVwfU8jNKXNSUl0MHznjlDxuUdTwwPQ12fg/XmumME7KJlHQcZHrXBytnvxUcFxJa3Mc8JIdDke/tXr4zCxrx/vLY8fC4qVCVn8L3PYNRjWaJzj71eTapZfY9Tk2j90+Sp/HkV6Jp2qpf6cswbdlenofSsrVdPiZFV0LLncCOoPevFwdV0KnvfM9zF0FiKXu+qPJZmHmuefvGonlAPJJqOW6/fOAAfmNIGZudma6jySdZWzntTmlLcAVCr4HzJTgyjn9KAJz5hTjimbMnJpBJuGBlaTDJ1bNACu20deKi80fSkJO7lvwpSm4HI5oAQsw78e1NHc9aaQyHpkUbixwBgUAO8xBwRg0hlx90g1FzuxtyaUYXJIxQBYWVXGGFRtHhvkyai8zn7ppwnYDAU0AAIU4YHNDOo6LzTS7NztH1puQT8xyaAF+XOcGlLgYGKjZ+3Sm0AOkf5qTJ9aaNp6nBozgdeKAHe4OTQWI65BpAwA4PNKC3fDUAKsqj3NSBt/IFR7wv8ABTkLfeAwKALkbDG3ODUg4561TJBOc8+1SK3y8E496AJ8kn5akVcctVdcAjD1MsxxgDNAFmN4ycHipBJGp+UZqojBmwwA+lSkHHy9KALQvNvBTiopJhIeSVFQDcCDn86kck4zigBwIYYReaNkmcsOlQbwHG081K0xJwc0ASJOM7XBxT5CUIaM8VXbD8ZpvmPGcdaANa21JwuOPxq0l3Izg4BrnxJk5bg1bimyB82KAOjhuSrAyqSPSuk0nWoQuxlA+tcHFdMmMNuFaNtOhwSDQB6bZ3kM5UAgfSt638g8Fvwry6wvzFgpkYrqNN1XzQPM4x3oA7gRRSIBGnzVUvdMWYYe3z+FUF1+OHaF5b1roNP1lZ41IUH1oA5O60OJY3PkYH0rmbvS1JZTHgD0Fe1LLBOgDRA56jFZep6DHMhaBAvtQB4rNosbg4LA1R/sgxsc84r1S78PvjDxkfSsK48PSeb8jED1NAHDG1ZvlC1Yit/s/L9+1dRJoNzGSyYc1mXmmXkbZkjbB9qAKa2BnG6MEA1LHpZTo4BrR03Sr+4XCZC+prXsvCk5kBupwF7gUAc8UWFMsQ5FW7TVYYxtaMnFdivhXTRH88hJ+tUL3RbC3QqgB96AOaurg3DZiiGKrNbPKME7Ae1ar2ezJh6etQwqQ/3CxoAzdR0VItGvJ/MyViY4/CuAU16Xr86po96hQqWiYfpXmK16OC+FnJiN0WENTKarIalU13pnKdR4FG/xDCB12kj617tIQ1hvU8leR714L4HcLri5OBt/rXuLTr9kLxsDuXke/rXzOba4j5I+nylf7PfzZ4l4ofPiS/8A95f5Vv8AgG9cLcWwPG4SAVymuuW17UGb7xl/pV7wpdm11iJgcA8H6V316XPgEuyTOCjU5Me33bR7TBdB7EnAyTj6VTedUlIk/i7VFbLuR1UllD5FY+tTzLexKgypO5vYDvXzUY3Pppy6nVWDDZuAwVOQRXBeNb+40+dktnCtLc/OSM5ULkj8a7bRGLoo4JOK8++JgI1GKTtvP54xXTgoqVaMZbXOTHyapSlHex2XhC/S702Ig8Y6entXP/Eiw+02jyxjMsJ8wY7juKo/Da/2yz2xY8fOP611urRLcxyJjBK5AHaqqReGrtLoyYSWIoJvqjw5myAR0qB25q3qsP2W/uIB91Wyv0PIqg7ZFfUwmpxUl1PlZwcJOL6Gt4d1X+z7wpM3+jS8N/s+9dzd6haQQRmWRNucK2evFeVOcUW77pcMSwC8AngVwYjBqpPnTt3O/DY+VKn7Nq/YwpoY/Pcr13GpEBA5NObBlkyP4jzTVC5Oa5hBjnlsinnytvBORR5Q7Uxos+30oAd5g29KR8kZFNRX9KkKNjkUAMUZ5xTWkYNz0p2XPAGBQwJGQQfagBuzfyCaQoqYycGlBY9BiggHk/jQAxgc53cU1ix5wCKmAUD5efrSZBOMUAMUF+gxTJSwOBxUzEYwMA1FtGck8+9AER3jqeKYVyeKnPzNjND7U9BQBD5ZPU5FMYFTwOKc7Ln92TmkOSOTg0ANyOynNKA2OcCkO7HBFNPvnNAEoUe1OIAxUCgEHPFKHKdORQBMxGOhpFckdaRWMhwODTwoQZJzQA1ZCOAMGpBuBywzTdyt0YZqeInGAQaAEypHIwaeGAH3jigZ3cqMU/huAKAGCQg4AxUiTOh9aRVHfrSKT0C0AWN/mHOMUjOuMEmomLDHFAwOpIoAlONuU600bz/EBTlZCuB+dRugHJJxQBLGVXqTmpgd+Oeap84/dmnRyMpwRQBYf5G5IpY+5JyKjZj1IwPWkbK8pQBbhlVRnB+lW4LjP3jgegrKDyEcgVPEjYDbsUAb8N3IrDafzrVt7mZfnZ/l9K5dJtigOfxrRsrqNVAd8igDsbG7SWPJGDXQ6LeyRAlm47ZrirK7t1AJbj0FXzqgJ+TAUdKAPULLUjgODk1sx6sGXBU5rx6x1mcPkMdo7ZrYtvEpVwHyaAPS1uQeXPB9aHs7a5XcWrkrTxDHsVn+bPataDW4GTKgKfSgDQXTYEcbOg9asPaQSLtaFTn1rNg1SO4bDYGO+avC9giQkyBvQUATR6XHGmIggPXilg0dZXPnHJPass67ESQpwwParkWvWyKC0mH9zQBHqHhKaV8wy7E96yLvw5dWinnzR6V0qeK7Rhtcg/jVuK/gu0LKy7T0oA8xlsLiOZsxkKf4aq3kUkKHavl16TdQQlmYuprBu47R3In59KAPOdbKHRb/AHtucQtj8q8wU9Oa9r8Z6fbf2DqMkAxsgc8fSvE1Ir0MH8LOXEbomU1Kpquh5qVDXcmcxs+HJWi1m1ZTg7sV7hbyK+nGQAKQmCBXgulbjqNsIzh/MGDXstnMf7Ml3Dayj5h6V4Gbx/exfkfRZNK9OUfM8l1V9+sXzD/nsRTbOcwXMcg/hPNUzKZZJZM/6yRmz+NOBr2KVNOioPtb8DxKtR+2lUXe/wCJ7foVwDaB0y0jqAo7dK5z4ku9tYlUYqZV8slTzgkZrS8DyifTIDnLFaz/AImjfpiy/wB1jXylKPLVSfRn1VaXNRbXY6DwPfrPp1vJ/GqAfQjiue+KEH+gC4H8EgJP1qH4aXe+OaBjkBv0NdF43sheaNcwqMsYzj61pUj7DENLoyKcvb4dN9Ueb+Erw2niG2Y/dc7G/GvU7iQGYBfvE7SfavD7WcxyQTDhkIb8RXqdnqKXNqsqNuJGciuzNKf7xVFs0cWV1f3bg+jPP/GkYj1VHUYWRCPxU1zrnjFdx44smNhFNj95Gd34HrXBO36134CpzUUux52Phy1m+4yQ9aLVv3p+lROcE0tqf3pz6V0yZypGU+/zHwwPzHigZJxnBoZQsr5YA7j/ADpxZQeRmvLO0kUkY3nj2qQOAQVyaiUqR0OfSpVORjbgUASlgy/3TUfzbsk8UjYXplqa8q8ZHPpQBIzA8Y4qPac/ItAfAztNWLa5H8QAoArhXzhh+dDx8cL1qzcTLJ92odoAzuOaAIhEw6LTHjkXqcVM8zgfKeKrmZmPzDNAChBnJP51ExBbDGpTh1+bik8oEcDI9c0ARHanQ1FK27pyfWpyu3Peoyf76gUAVwjDngUvQHdk07cR90cUw/Mcu2KADeO3FITk5JzQ5xjbg+9GTjtQAmST8tIxJHJxTwGPJ7dqayZ6jAoAfCMHINSM2T8p4qBSFPGfepGYMPl/KgAZRnI5qeJzn5Rg1WVgCOxqQseo5NAFoykH5hmkEw6jIqJJB3BzQ8pxkKKALCurAnmngAjIJFUhMx6Yp+9x/FmgC0Tk+1Iy7vuGq+WzyakDKOmc0AP2uD94Ck5zgtUbgtzmnKAME9fU0ASK2ztTlcBTuqvIS3CfpTRGSPmb8KALsbl16fLQXIb2qtHNsBUVMJBgdPrQBMUJ5B5PapVJUAE5qswJHyNnNKHIwG4oAurMFUBlyPWrNsI2IJGAaowvuHODTvuODnPsKAOgS5gjIz1q3FLDNghvwrmxN/eGDUsEmw7g3NAHTjEbZDlQe1SrMVOSdymsWK9LjkbqlFw+MKQBQB0dvqHlcIC1aEGotJ98MvtXMWEqxnLOCTWtHcArh3APagDSfUmVsJIy1Ot9KIi3msxPvWSTEUwWJ9xSxzQgbXJAFAGhDrMobBTvyalub+OdBhtrVh3U1vjEchqmZkPIkoA1VvZIZvlYtV9PEV3bgbSQPTNco95IWwuD70LdfL87fNQB2UXiy6ZssGI9KnGvecczZHtXDteORiMYFTWt+f48EigDpPEupyy6DepEwMbQsG+mK8kBrvr+aefR74hQqCFifyrz5TzXdhNmc1fdFhTUqGq6mpVPNdqZzWNfw8N2t2S/9NK9S1qcWPh/UJc4Pkkj69K8o0GZYdYtJHOFDjJrsPiRqSiyt7CNwXuMM4HZBXkZhB1K8Irr/me3ltRUsPOb6f5HDw/LGg/2RmpQag3U4NXsniHpfw7uC2n7VbDIxFa/jyATaHOF5Kx7/wBK5L4cXGJ7iE4zkMK73V4xPp0qHqUIr5PFx9niJetz6vCSVTDx9Lfoee/Dy6KamUz/AKyIH8RXqN0fMtx3yvNeK+Fp/suuWeTgCQxN+eK9miZWVg2AmOea2zKP75TX2kmYZbP9zyPo2jxLWLc2WrXdvj5Vcsv0PIrV8GakLe/EEpzE/wB3PY0vj+PZqlvNjBkVoz9VPFc3BKYbiOQH7rA16UEsThEnvb8UebUf1fFNra/4M9S19Uuo1XqCMEV5JexNb3UsDcFGI/DtXqUD+bAp6krkGuB8aQ+VqodRw6AHHqK4cvq8tTl7nbmFPmpc3Y59yKW1P74/So3PFLaH9830r1pM8eKM93VZXypJ3GnB844xSJtMrk8nJpzsMgDmvOOsmRD1U0MX6YOaRJWUdMCpC/8AEp5oAIyRwRTXCA5xk013LkbiBSAgHG7NAEnm8cDimSMo5xyaR2AGRzURdMjNAEodiMjigtnqRmojMo4BqMMSelAFkHsSKTAByCDUOD680gbb060ATqVZvn4FEhRR+7I/OoTICvJzURdaAHO5wPWo3YsPm6U15M96iIyeSaAHljnAIxTWKk8rScg8UoJHGKAEzgYVcim7gD0INPBIGentQ2Dg96AEXnlSaWRjnvQOh5/KlBXuTQA1evrRyrZzSYAPWnKGH0oACyk8jmnrgDOcCmDj+Gl5PXmgBe+Q2BSnpw2ab7AcUuDQALluBinhQpw1Ii4Occ0rAMMk0AOLBTT85ANQhGGDUoYkDoBQAobLYOaWTP8ACeKTcvTv603KjoTmgB0eRxyKcAf71NDqfvZzSnb1Tk0AOEW48mp44tvXmoo9454qcK5oAfhccgg+1AxjGM0ojkUDNOI454NADVO0ZJ59KljnXB4+amqhPoaTY3IABNAF6Lay5YGlYxqPkU1Uid14cjHpVlHjB4PPvQBJbyMCeDUhmfnah+tCyFuVwBUiOQeGH0oAt6cVC5kPJ7GtJJ0J+ZcY6VkxiInL5BqyApA2ZIoA0xdY4TaRVeeeVjnjHtUflEKCq02SCVl44FADoi3OVB+tODxFsMoB+tVTDOvBbimNtDBWGSe9AFmcQjlHANQ7lJHKg1WnhVQW5xVVncDgcUAaskkYT53GfamRTKso8v5vas1MjqN1W7IxLlmbDUAbd7Of7Hu1YYzEwwD7VwimuivbhfsU6iQnKEVzSnp6V2YZ6M5625OpqRTUANSKa7EznaLCnvT3dpJDJI7PIQBljk4HaoAeKcGqrJu7C7SsiTPNODcVECKduqiTpvA85i1tQMfOhHNeryhms5G2luOp4wK8V8NzLFrlmznC7tp/GvYRfFtNmjdtq7DwOS3pmvnczhatfuj6LK5Xo27M8g1VTY67eKvBjm3r+PNet2WoxvYxT4yWjH+RXlnjJSviOcn+KJD+lbXg7UZpbY2wIYx8Dd2FaYmn7TDU6nbQyw81TxFSn3dyP4ghpFtpmH3ZiSPTIrjWPUV6N4osjcaTJH1kPzA+9eaFvXg10ZbO9Nx7HLmMP3il3O88MagJtKVHP7yM7CT6Vm+Jrdrm3ncKQYh5ik9xWR4fmZLtolOBIv54rpNbmVdNmmY9Yiv5iuOrT9jX93vc76U1Ww/vdrM87kORS2h/en6VG/GBS2Z/fNn+7XpyZ40UU5V3SP8ANgbjQh2txk06SGRpX+ToxHUetSw20mPu4/EVxHSMLMOSePSk+XqCRVpoX4BT9RTfssvZR+YoAiGSKaCTwRVlbeT+7j8RS/ZJeoX9RQBUlD7cHgU1IgRkNk1ea3lK4KZ/EVTeGVWwq4/EUARsjDqPypNrleGGKlKTHjZz9RUXkz7jlf1FACA7Rzkn1pTKQcDmnfZ3PJBz9RTTA/8ACvP1FAEbjP3jg0z5cdCanNvKRyn6immCU8bOPqKAIGbHQAUM2amktJOMJ+opBaS4+5+ooAhVhnGKQjnnNTi3lzwn6ihrebPC/qKAIcDHFIBnNT/Zpu6/qKFt5Rzs/UUAQ4wPmpytxwM0/wCzSsclf1FL9ml6BP1FAEfB9qcqkDBNP+zS54X9RTlimB/1YP4igCGRTuznikYHrVsWsr4Yrj8RTvskjdFx+IoAoAHPNSqVxyDmrH2OVW5TP4ipfsUjDJXn6igCqBk04oPWntazIchc/iKURSEZKfqKAIiSO2acRlelPEcjHHl8fUU828icqmR9RQBEAMfKvNKQpHK8+tSCKXPCY/EVKLebH3f1FAFVlxjHSgj2q2bSQj7nP1FNFvKF+5+ooAhX5R941YgcMPSoxDLnlOfqKsR28uOY+fqKAJYpAOCfzqVtj4z+dEVszL+8T9RTTBIrHauR7kUANkixgociiLIbgdakSOTHKE/iKUJKCcLg/UUAK0RY5IApGjG4fMCKEefOGTI+oq1BCxBJTH4igCJGRT0NTrtIyinNOEH92Pn61KICeoOfqKAFgfy+XA57VcG0qGHy1VWBkGVXJ9zSxwzP95SB9RQBc8wKBtc5qKRpXOVl470CGRV4XP4imtbz43EfL7EUAHLDAmyaquSkmXO6pmi2/wAB/OoWjlHRePqKAJSwK7g2PY1Um2t1cCnSW0zLkjj61U+zS5OVz+IoAfufOFelZv4R1phhnVflXj6ijyXZcspB9iKAFmk220i5BO01loauSowRl2/MR61VWCUfwfqK6qD0ZjVHA4qRTTVgl7r+oqRYZefl/UV1JmDQoOKcD70gglzyvH1FO8iX+7+oq0ybCgilBoEEv939RThDL/d/UU+YLDoZPLlRx/CQa9P0y5a4skIPDgDjuK8vWGX+7+oruPAssv2ZoZAfkOBz2ry8zheKn2PSy2pyycO5nePYSmpRT9mXaay/Dt21rqsZBxv+U11vjaye401pVXmP5hkiuBhWWOaOQL91geop4X97hnTYYr93iFU7nqLyGdBnkAc15lrUX2bVJ48YBbcPxr0qzVjb7gpCsATz1riPGNpIb1ZgvB+U8iuPAz5atu51Y6HNSv2MCGdoJkljPzocir+ra017p6W4jKHdlzn9KzWhl/u/qKheGU/w/qK9OpCMpKT3R5lOrKEXFPRleQ06zP70/wC7SPBLyNv6in2cEvnEbedvqPaokxJH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ultrasound image shows the third extensor compartment of the wrist. The image was obtained with the ultrasound probe placed at the site of the red mark in the photograph.",
"    <div class=\"footnotes\">",
"     ECRB: extensor carpi radialis brevis tendon; LT: Listers tubercle; EPL: extensor pollicis longus tendon; IV: fourth extensor compartment.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Blake Boggess, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30033=[""].join("\n");
var outline_f29_21_30033=null;
var title_f29_21_30034="Clutton joints";
var content_f29_21_30034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital syphilis: Clutton joints",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with congenital syphilis shows \"Clutton joints,\" or symmetrical hydrarthrosis of the knee joint. This is a painless condition that often occurs during the late stages of congenital syphilis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: the Public Health Image Library, Centers for Disease Control and Prevention. Photo by Susan Lindsley.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30034=[""].join("\n");
var outline_f29_21_30034=null;
var title_f29_21_30035="EP study tracings bundle branch reentrant VT";
var content_f29_21_30035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface ECG recordings during electrophysiologic study of bundle branch reentrant ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are five surface ECG leads (I, II, aVF, V1, V6) and intracardiac recordings from the high right atrium (HRA3-4), His bundle region (HBE1-2), and the right ventricular apex (RVA3-4). The atrial and ventricular (V) electrograms are dissociated, confirming a ventricular tachycardia; however, a His bundle depolarization (H) precedes each ventricular electrogram. Further testing confirmed the diagnosis of bundle branch reentrant ventricular tachycardia (BBRVT), a macroreentrant ventricular tachycardia involving the left and right bundle branches. During typical BBRVT, the wavefront goes down the right bundle, across the interventricular septum, and then retrograde up the left bundle, with passive retrograde activation of the His bundle. Since both bundle branches are necessary parts of the macroreentry circuit, catheter ablation of the right bundle branch is curative.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30035=[""].join("\n");
var outline_f29_21_30035=null;
var title_f29_21_30036="Biliary reconstruction with Roux-en-Y hepaticojejunostomy";
var content_f29_21_30036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Biliary reconstruction with Roux-en-Y hepaticojejunostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 629px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The most common reconstruction for proximal bile duct injury is Roux-en-Y hepaticojejunostomy. Biliary stent placement helps reduce stricture at the anastomosis. Once a silastic stent has been positioned to replace the prior drainage catheter, the small bowel is divided and the distal small bowel (Roux limb) brought up and sutured to the bile duct (end-to-side hepaticojejunostomy). An end-to-side bowel-bowel anastomosis completes the Roux-en-Y reconstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30036=[""].join("\n");
var outline_f29_21_30036=null;
var title_f29_21_30037="Periocular syringomas";
var content_f29_21_30037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Syringomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple skin-colored papules are present on the periocular skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30037=[""].join("\n");
var outline_f29_21_30037=null;
var title_f29_21_30038="Vascular lesions in the newborn";
var content_f29_21_30038=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vascular lesions in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/21/30038/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30038/contributors\">",
"     Josie A Pielop, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/21/30038/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30038/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30038/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/21/30038/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30038/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/21/30038/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular lesions are common in newborns. The majority of vascular lesions are benign and self-limited conditions, although some are signs of systemic disorders or associated with complications.",
"   </p>",
"   <p>",
"    There are two general categories of vascular lesions: benign vascular neoplasms and vascular malformations. Benign vascular neoplasms, such as hemangiomas, are characterized by proliferation of endothelial cells, while vascular malformations have normal endothelial turnover.",
"   </p>",
"   <p>",
"    Vascular lesions in the newborn will be reviewed here. Other neonatal skin lesions and inherited skin disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=see_link\">",
"     \"Vesiculobullous and pustular lesions in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6840?source=see_link\">",
"     \"Skin nodules in newborns and infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7447?source=see_link\">",
"     \"Congenital melanocytic nevi and speckled lentiginous nevi\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link\">",
"     \"The genodermatoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMANGIOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangiomas, which are also called infantile hemangiomas, and hemangiomas of infancy are the most common benign tumors of infancy. The pathophysiology, clinical features, complications, evaluation, and management of infantile hemangiomas are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5495?source=see_link\">",
"     \"Evaluation and diagnosis of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link\">",
"     \"Management of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VASCULAR MALFORMATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular malformations are anomalies of morphogenesis and are always congenital. Unlike neoplasms, endothelial turnover is normal. They are categorized as capillary, venous, arterial, lymphatic, or combined groups or as low-flow (capillary, venous, lymphatic, or combination) and high-flow (arterial, arteriovenous) lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vascular malformations are always present at birth but often are clinically subtle. They become more apparent over time as they slowly expand in proportion to the infant's overall growth; in addition, there is progressive ectasia secondary to changes in blood or lymphatic flow, pressure associated with trauma, or hormonal changes such as at puberty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nevus simplex (macular stain)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nevus simplex (also called macular stain, salmon patch, stork bite, or angel kiss) presents as single or multiple blanchable, pink-red patches in newborn infants (",
"    <a class=\"graphic graphic_picture graphicRef70234 graphicRef72513 graphicRef81729 \" href=\"UTD.htm?28/37/29273\">",
"     picture 1A-C",
"    </a>",
"    ). These lesions occur in 40 to 60 percent of infants, most commonly on the eyelid, glabella, and midline of the nape of the neck. Less common sites of involvement include the scalp, nose, lip, and back [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/2\">",
"     2",
"    </a>",
"    ]. Nevus simplex generally fades within one to two years, although lesions on the back of the neck may persist unchanged with little consequence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, nevus simplex may be associated with extracutaneous disorders such as spinal dysraphism, Beckwith-Wiedemann syndrome, macrocephaly-capillary malformation syndrome, or other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link\">",
"     \"Beckwith-Wiedemann syndrome\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Cutis marmorata telangiectatica congenita'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with lumbosacral nevus simplex, imaging studies to evaluate for underlying spinal dysraphism are recommended when another lumbosacral abnormality such as a dermal sinus or pit, lipoma, patch of hypertrichosis, or deviated gluteal cleft is present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/2\">",
"     2",
"    </a>",
"    ]. It is unclear whether spinal imaging should be routinely performed in patients with isolated lumbosacral nevus simplex, as the risk of underlying spinal abnormalities may be low in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. We typically do not image patients in the absence of other lumbosacral abnormalities. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Port wine stains",
"    </span>",
"    &nbsp;&mdash;&nbsp;A port wine stain (PWS), or nevus flammeus, is a low flow capillary malformation that can occur anywhere on the body (",
"    <a class=\"graphic graphic_picture graphicRef59124 graphicRef73978 graphicRef54078 \" href=\"UTD.htm?30/0/30729\">",
"     picture 2A-C",
"    </a>",
"    ). They are present in 0.1 to 0.3 percent of newborns.",
"   </p>",
"   <p>",
"    The lesions are pink or red patches that are unilateral in 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. They enlarge proportionally to the child's growth and persist in approximately 40 to 60 percent of affected patients, darkening and developing raised nodular or plaque-like components in adults.",
"   </p>",
"   <p>",
"    Pulsed dye laser therapy is an effective treatment for PWS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Factors such as patient age and lesion location can affect the response to therapy. Although recurrence of PWS in the years following treatment may occur, lesions usually remain lighter in color than they were before treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Complications of pulsed dye laser therapy include scarring and transient hyperpigmentation, and retinal injury can occur if the eyes are not shielded properly. Laser therapy for PWS is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H10061356#H10061356\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Port wine stains'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While most PWS are isolated anomalies, they may be associated with developmental defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sturge-Weber syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sturge-Weber syndrome is a rare congenital but not hereditary vascular disorder characterized by a facial capillary malformation involving the V1",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    V2 dermatome and an associated leptomeningeal vascular malformation (",
"    <a class=\"graphic graphic_picture graphicRef60560 graphicRef73343 \" href=\"UTD.htm?9/12/9415\">",
"     picture 3A-B",
"    </a>",
"    ). These malformations may be associated with specific ocular (predominantly glaucoma) and neurologic abnormalities, including seizures, hemiparesis, intellectual disability (mental retardation), and behavior problems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=see_link\">",
"     \"Sturge-Weber syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sturge-Weber syndrome is rare, occurring in approximately 10 percent of patients with facial PWS involving V1. Patients with bilateral facial PWS, involvement of multiple dermatomes of the trigeminal nerve, or complete involvement of V1 are at even higher risk of neuro-ocular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/9,14,15\">",
"     9,14,15",
"    </a>",
"    ]. PWS that spare the forehead and eyelids are almost never associated with neurologic or ocular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. Given these findings, it is reasonable to screen for eye and CNS disease for PWS involving the eyelids; unilateral lesions involving V1, V2, and V3; or bilateral lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CNS abnormalities of Sturge-Weber syndrome are best demonstrated with magnetic resonance imaging (MRI) with gadolinium enhancement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/17\">",
"     17",
"    </a>",
"    ]. Given the need to sedate infants for MRI, it is reasonable to perform imaging in this age group only if neurologic abnormalities are detected. MRI may not detect all vascular malformations in young infants, so a negative scan should be repeated if the diagnosis of Sturge-Weber is suspected. Cortical calcifications adjacent to leptomeningeal lesions are best seen on computed tomography (CT) scan, but may not be evident in infancy. Hyperperfusion of the cerebral cortex of the involved hemisphere may be seen with single photon emission computed tomography (SPECT) in the first year of life before the onset of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Klippel-Trenaunay syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klippel-Trenaunay syndrome is an extensive PWS with underlying venous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphatic malformations involving an extremity (",
"    <a class=\"graphic graphic_picture graphicRef51296 \" href=\"UTD.htm?24/34/25121\">",
"     picture 4",
"    </a>",
"    ). Increased angiogenesis is a mechanism for these lesions, and mutations in the gene for an angiogenic factor (VG5Q) that result in increased transcription or activity have been identified in some patients with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/19\">",
"     19",
"    </a>",
"    ]. VG5Q is expressed in blood vessels, is secreted during vessel formation, and promotes endothelial cell proliferation.",
"   </p>",
"   <p>",
"    The lower limb, upper limb, or both are affected in 95, 5, and 15 percent of cases, respectively, and the majority are unilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/8\">",
"     8",
"    </a>",
"    ]. The capillary lesion is associated with soft tissue swelling and bony hypertrophy. In Parkes-Weber syndrome (also called Klippel-Trenaunay-Weber syndrome), there are additional underlying arteriovenous anastomoses. Because discrepancies often occur in leg length in these disorders, close orthopedic follow-up is required [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cutis marmorata telangiectatica congenita",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutis marmorata telangiectatica congenita (CMTC, also called nevus vascularis reticularis and congenital livedo reticularis) is a vascular anomaly characterized by a generalized or localized reticulated cutaneous vascular network. Like cutis marmorata (",
"    <a class=\"graphic graphic_picture graphicRef50846 \" href=\"UTD.htm?3/61/4050\">",
"     picture 5",
"    </a>",
"    ), it may be accentuated by cold. However, unlike cutis marmorata, the cutaneous abnormalities do not usually resolve with rewarming and exhibit a coarser vasculature which may be associated with skin atrophy and ulceration (",
"    <a class=\"graphic graphic_picture graphicRef64092 graphicRef74935 \" href=\"UTD.htm?19/51/20277\">",
"     picture 6A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H14#H14\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Cutis marmorata'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In more than two-thirds of cases, CMTC affects the limbs (especially the legs), which may become discrepant in size and shape [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/21\">",
"     21",
"    </a>",
"    ]. The face and trunk are less commonly affected. Lesions are unilateral in 65 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/21\">",
"     21",
"    </a>",
"    ]. They usually fade or resolve spontaneously within two years, but rarely may persist unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/8,22\">",
"     8,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No sex predominance has consistently been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Associated abnormalities have been reported to occur in 27 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. These include PWS, body and limb asymmetry, glaucoma (especially with facial involvement), localized aplasia cutis congenita, cleft palate, or other malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/22,24\">",
"     22,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3092011\">",
"    <span class=\"h2\">",
"     Macrocephaly-cutis marmorata telangiectatica congenita",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrocephaly-cutis marmorata telangiectatica congenita (M-CMTC, macrocephaly-capillary malformation, MIM 602501) is an overgrowth syndrome with clinical features that may include capillary malformations, macrocephaly,",
"    <span class=\"nowrap\">",
"     polydactyly/syndactyly,",
"    </span>",
"    neonatal hypotonia, developmental delay, and structural brain abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Although the reticulated appearance of skin lesions in M-CMTC can resemble CMTC, they are most consistent with capillary malformations. This has prompted some authors to suggest this condition be renamed Macrocephaly-Capillary Malformation (M-CM) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/29\">",
"     29",
"    </a>",
"    ]. The vascular lesions often fade during the first few years of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Phakomatosis pigmentovascularis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phakomatosis pigmentovascularis (PPV) is the term used when vascular malformations and melanocytic nevi or dermal melanocytosis occur in the same patient. The etiology is thought to be a developmental abnormality of the vasomotor nerves and melanocytes, both derived from neural crest [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/1\">",
"     1",
"    </a>",
"    ]. All racial and ethnic groups may be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/30\">",
"     30",
"    </a>",
"    ]. Multiple types of PPV have been identified, the most common being phakomatosis cesioflammea (PWS plus blue spots such as nevus of Ota or Mongolian spots), formerly known as PPV types IIa and IIb [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7447?source=see_link\">",
"     \"Congenital melanocytic nevi and speckled lentiginous nevi\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=see_link&amp;anchor=H14#H14\">",
"     \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Dermal melanocytosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H18#H18\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Scalp lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Capillary malformation is present in most PPV types and is usually extensive. In one series of 15 PPV cases, all had facial capillary malformations, and 80 percent had additional capillary malformations in other areas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/31\">",
"     31",
"    </a>",
"    ]. As many as half of patients have other associated cutaneous lesions, most commonly nevus anemicus and caf&eacute;-au-lait spots [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been estimated that approximately 50 percent of patients have systemic involvement; neurologic, ocular, and skeletal abnormalities occur most frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Neurologic abnormalities usually present in the first few months of life and include psychomotor retardation, seizures, intracranial calcifications, or cerebral atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30038/abstract/33\">",
"     33",
"    </a>",
"    ]. Ocular involvement, such as blue-gray scleral discoloration, is also common. Management and outcome depend upon the presence of other associated conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23409084\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular malformations may be composed of capillary, venous, arterial, or lymphatic vessels. Lesions are present at birth, but may become more apparent over time. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nevus simplex most commonly presents in newborn infants as an erythematous patch on the nape of the neck, eyelid, or glabella. Lesions often resolve within one to two years. Some lesions, particularly those on the posterior neck, may persist throughout life. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nevus simplex (macular stain)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Port-wine stains are low-flow capillary malformations that may occur on any area of the body. Lesions may become darker, plaque-like, and nodular with age. Pulsed-dye laser therapy is an effective treatment for port-wine stains. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Port wine stains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sturge-Weber syndrome is a rare congenital disorder that presents with a facial capillary malformation involving the V1 distribution accompanied by ocular",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurologic abnormalities. Approximately 10 percent of patients with facial capillary malformations in the V1 distribution have Sturge-Weber syndrome. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sturge-Weber syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Klippel-Trenaunay syndrome is characterized by vascular malformations and tissue hypertrophy affecting one or more extremities. The leg is the most common site of involvement. Because limb length discrepancies often occur, patients with Klippel-Trenaunay syndrome usually require orthopedic care. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Klippel-Trenaunay syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutis marmorata telangiectatica congenita (CMTC) is a vascular anomaly that presents with reticulated vascular patterns on the skin of infants. Coarse vasculature and foci of atrophy or ulceration differentiate this disorder from cutis marmorata. CMTC usually resolves within two years. Other cutaneous and extracutaneous disorders may occur in association with CMTC. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cutis marmorata telangiectatica congenita'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Macrocephaly-cutis marmorata telangiectatica congenita (CMTC) is an overgrowth syndrome that presents with cutaneous lesions that may resemble CMTC clinically, but are most consistent with capillary malformations. Neurologic and limb abnormalities can also occur in this syndrome. (See",
"      <a class=\"local\" href=\"#H3092011\">",
"       'Macrocephaly-cutis marmorata telangiectatica congenita'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Phakomatosis pigmentovascularis (PPV) describes the occurrence of vascular malformations with disorders of pigmentation (eg, nevus of Ota or mongolian spots). Neurologic, ocular, and skeletal disorders may occur in patients with PPV. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Phakomatosis pigmentovascularis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/1\">",
"      Requena L, Sangueza OP. Cutaneous vascular anomalies. Part I. Hamartomas, malformations, and dilation of preexisting vessels. J Am Acad Dermatol 1997; 37:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/2\">",
"      Juern AM, Glick ZR, Drolet BA, Frieden IJ. Nevus simplex: a reconsideration of nomenclature, sites of involvement, and disease associations. J Am Acad Dermatol 2010; 63:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/3\">",
"      Cohen BA. Hemangiomas in infancy and childhood. Pediatr Ann 1987; 16:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/4\">",
"      Metzker A, Shamir R. Butterfly-shaped mark: a variant form of nevus flammeus simplex. Pediatrics 1990; 85:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/5\">",
"      Oakes WJ. Butterfly-shaped mark. Pediatrics 1991; 87:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/6\">",
"      Patrizi A, Neri I, Orlandi C, Marini R. Sacral medial telangiectatic vascular nevus: a study of 43 children. Dermatology 1996; 192:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/7\">",
"      Ben-Amitai D, Davidson S, Schwartz M, et al. Sacral nevus flammeus simplex: the role of imaging. Pediatr Dermatol 2000; 17:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/8\">",
"      Dohil MA, Baugh WP, Eichenfield LF. Vascular and pigmented birthmarks. Pediatr Clin North Am 2000; 47:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/9\">",
"      Tallman B, Tan OT, Morelli JG, et al. Location of port-wine stains and the likelihood of ophthalmic and/or central nervous system complications. Pediatrics 1991; 87:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/10\">",
"      Reyes BA, Geronemus R. Treatment of port-wine stains during childhood with the flashlamp-pumped pulsed dye laser. J Am Acad Dermatol 1990; 23:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/11\">",
"      Faurschou A, Togsverd-Bo K, Zachariae C, Haedersdal M. Pulsed dye laser vs. intense pulsed light for port-wine stains: a randomized side-by-side trial with blinded response evaluation. Br J Dermatol 2009; 160:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/12\">",
"      Soueid A, Waters R. Re-emergence of port wine stains following treatment with flashlamp-pumped dye laser 585 nm. Ann Plast Surg 2006; 57:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/13\">",
"      Huikeshoven M, Koster PH, de Borgie CA, et al. Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment. N Engl J Med 2007; 356:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/14\">",
"      Enjolras O, Riche MC, Merland JJ. Facial port-wine stains and Sturge-Weber syndrome. Pediatrics 1985; 76:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/15\">",
"      Mehta M, Salas AH, Fay A. Trigeminal dermatome distribution in patients with glaucoma and facial port wine stain. Dermatology 2009; 219:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/16\">",
"      Sujansky E, Conradi S. Sturge-Weber syndrome: age of onset of seizures and glaucoma and the prognosis for affected children. J Child Neurol 1995; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/17\">",
"      Mart&iacute;-Bonmat&iacute; L, Menor F, Poyatos C, Cortina H. Diagnosis of Sturge-Weber syndrome: comparison of the efficacy of CT and MR imaging in 14 cases. AJR Am J Roentgenol 1992; 158:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/18\">",
"      Pinton F, Chiron C, Enjolras O, et al. Early single photon emission computed tomography in Sturge-Weber syndrome. J Neurol Neurosurg Psychiatry 1997; 63:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/19\">",
"      Tian XL, Kadaba R, You SA, et al. Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 2004; 427:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/20\">",
"      Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol 1993; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/21\">",
"      Amitai DB, Fichman S, Merlob P, et al. Cutis marmorata telangiectatica congenita: clinical findings in 85 patients. Pediatr Dermatol 2000; 17:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/22\">",
"      Kienast AK, Hoeger PH. Cutis marmorata telangiectatica congenita: a prospective study of 27 cases and review of the literature with proposal of diagnostic criteria. Clin Exp Dermatol 2009; 34:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/23\">",
"      Picascia DD, Esterly NB. Cutis marmorata telangiectatica congenita: report of 22 cases. J Am Acad Dermatol 1989; 20:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/24\">",
"      Pehr K, Moroz B. Cutis marmorata telangiectatica congenita: long-term follow-up, review of the literature, and report of a case in conjunction with congenital hypothyroidism. Pediatr Dermatol 1993; 10:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/25\">",
"      Devillers AC, de Waard-van der Spek FB, Oranje AP. Cutis marmorata telangiectatica congenita: clinical features in 35 cases. Arch Dermatol 1999; 135:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/26\">",
"      Mart&iacute;nez-Glez V, Romanelli V, Mori MA, et al. Macrocephaly-capillary malformation: Analysis of 13 patients and review of the diagnostic criteria. Am J Med Genet A 2010; 152A:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/27\">",
"      Katugampola R, Moss C, Mills C. Macrocephaly-cutis marmorata telangiectatica congenita: A case report and review of salient features. J Am Acad Dermatol 2008; 58:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/28\">",
"      Garavelli L, Leask K, Zanacca C, et al. MRI and neurological findings in macrocephaly-cutis marmorata telangiectatica congenita syndrome: report of ten cases and review of the literature. Genet Couns 2005; 16:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/29\">",
"      Wright DR, Frieden IJ, Orlow SJ, et al. The misnomer \"macrocephaly-cutis marmorata telangiectatica congenita syndrome\": report of 12 new cases and support for revising the name to macrocephaly-capillary malformations. Arch Dermatol 2009; 145:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/30\">",
"      Vidaurri-de la Cruz H, Tamayo-S&aacute;nchez L, Dur&aacute;n-McKinster C, et al. Phakomatosis pigmentovascularis II A and II B: clinical findings in 24 patients. J Dermatol 2003; 30:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/31\">",
"      Fern&aacute;ndez-Guarino M, Boixeda P, de Las Heras E, et al. Phakomatosis pigmentovascularis: Clinical findings in 15 patients and review of the literature. J Am Acad Dermatol 2008; 58:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/32\">",
"      Huang C, Lee P. Phakomatosis pigmentovascularis IIb with renal anomaly. Clin Exp Dermatol 2000; 25:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30038/abstract/33\">",
"      Van Gysel D, Oranje AP, Stroink H, Simonsz HJ. Phakomatosis pigmentovascularis. Pediatr Dermatol 1996; 13:33.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5789 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-37932DBF7B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30038=[""].join("\n");
var outline_f29_21_30038=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23409084\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMANGIOMAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VASCULAR MALFORMATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nevus simplex (macular stain)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Port wine stains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sturge-Weber syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Klippel-Trenaunay syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cutis marmorata telangiectatica congenita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3092011\">",
"      Macrocephaly-cutis marmorata telangiectatica congenita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Phakomatosis pigmentovascularis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23409084\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5789\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5789|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/38/19040\" title=\"picture 1A\">",
"      Salmon patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/60/5059\" title=\"picture 1B\">",
"      Macular stain - neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/4/27714\" title=\"picture 1C\">",
"      Macular stain - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/32/18946\" title=\"picture 2A\">",
"      Port wine stain - V2 infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/45/722\" title=\"picture 2B\">",
"      Port wine stain - V2 child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/24/34177\" title=\"picture 2C\">",
"      Port wine stain - leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/21/33105\" title=\"picture 3A\">",
"      Sturge-Weber syndrome - bilateral PWS infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/61/2002\" title=\"picture 3B\">",
"      Bilateral port wine stains in SWS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/34/25121\" title=\"picture 4\">",
"      Klippel-Trenaunay syndrome - leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/61/4050\" title=\"picture 5\">",
"      Cutis marmorata - legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/34/42528\" title=\"picture 6A\">",
"      Cutis marmorata telangiectatica congenita - arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/2/5152\" title=\"picture 6B\">",
"      Cutis marmorata telangiectatica congenita - leg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=related_link\">",
"      Benign pigmented skin lesions other than melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7447?source=related_link\">",
"      Congenital melanocytic nevi and speckled lentiginous nevi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5495?source=related_link\">",
"      Evaluation and diagnosis of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=related_link\">",
"      Laser and light therapy for cutaneous vascular lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=related_link\">",
"      Management of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6840?source=related_link\">",
"      Skin nodules in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=related_link\">",
"      Sturge-Weber syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=related_link\">",
"      Vesiculobullous and pustular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_21_30039="Pityriasis rubra pilaris face and scalp involvement";
var content_f29_21_30039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pityriasis rubra pilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse erythema and scale are present on the face and scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30039=[""].join("\n");
var outline_f29_21_30039=null;
var title_f29_21_30040="Nortriptyline: Drug information";
var content_f29_21_30040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nortriptyline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/22/25957?source=see_link\">",
"    see \"Nortriptyline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/26/38310?source=see_link\">",
"    see \"Nortriptyline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pamelor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nortriptyline&reg;;",
"     </li>",
"     <li>",
"      Ava-Nortriptyline;",
"     </li>",
"     <li>",
"      Aventyl&reg;;",
"     </li>",
"     <li>",
"      Dom-Nortriptyline;",
"     </li>",
"     <li>",
"      Norventyl;",
"     </li>",
"     <li>",
"      Nu-Nortriptyline;",
"     </li>",
"     <li>",
"      PMS-Nortriptyline;",
"     </li>",
"     <li>",
"      Teva-Nortriptyline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F202751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tricyclic (Secondary Amine)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F202717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: 25 mg 3-4 times/day up to 150 mg/day; doses may be given once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic urticaria, angioedema, nocturnal pruritus (unlabeled use):",
"     </b>",
"     Oral: 75 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Myofascial pain, neuralgia, burning mouth syndrome (unlabeled uses):",
"     </b>",
"     Initial: 10-25 mg at bedtime; dosage may be increased by 25 mg/day weekly, if tolerated; usual maintenance dose: 75 mg as a single bedtime dose or 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Smoking cessation (unlabeled use; Fiore, 2008):",
"     </b>",
"     Oral: Initial: 25 mg/day; titrate dose to 75-100 mg/day 10-28 days prior to selected &ldquo;quit&rdquo; date; continue therapy for &ge;12 weeks after &ldquo;quit&rdquo; day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of nortriptyline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing nortriptyline and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate nortriptyline in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving nortriptyline and potential benefits outweigh potential risks, discontinue nortriptyline  promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume nortriptyline 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F202732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/26/38310?source=see_link\">",
"      see \"Nortriptyline: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nocturnal enuresis (unlabeled use):",
"     </b>",
"     Oral: 10-20 mg/day; titrate to a maximum of 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression (unlabeled use):",
"     </b>",
"     Oral: 1-3 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F202718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Initial: 30-50 mg/day, given as a single daily dose or in divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     Nortriptyline is one of the best tolerated TCAs in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F202719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lower doses and slower titration are recommended dependent on individualization of dosage.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 10 mg, 25 mg, 50 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pamelor&trade;: 10 mg, 25 mg, 50 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 10 mg/5 mL (473 mL, 480 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pamelor&trade;: 10 mg/5 mL (480 mL [DSC]) [contains benzoic acid, ethanol 4%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088671.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088671.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F202694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptoms of depression",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F202748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic pain (including neuropathic pain), myofascial pain, burning mouth sydrome, anxiety disorders, attention-deficit/hyperactivity disorder (ADHD); enuresis; adjunctive therapy for smoking cessation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F202760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aventyl&reg; HCl may be confused with Bentyl&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nortriptyline may be confused with amitriptyline, desipramine, Norpramin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pamelor&trade; may be confused with Demerol&reg;, Tambocor&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (SIADH: Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F202749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, flushing, heart block, hypertension, MI, orthostatic hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, delirium, delusions, disorientation, dizziness, drowsiness, EEG changes, exacerbation of psychosis, extrapyramidal symptoms, fatigue, hallucinations, headache, hypomania, incoordination, insomnia, nightmares, panic, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, itching, petechiae, photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Blood sugar increased/decreased, breast enlargement, galactorrhea, gynecomastia, libido increased/decreased, sexual dysfunction, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, black tongue, constipation, diarrhea, epigastric distress, nausea, paralytic ileus, stomatitis, taste disturbance, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Delayed micturition, impotence, nocturia, polyuria, testicular edema, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis (rare), eosinophilia, purpura, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness, paresthesia, peripheral neuropathy, tingling, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, disturbances in accommodation, eye pain, mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions (eg, general edema or of the face/tongue), diaphoresis (excessive),  withdrawal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F202697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nortriptyline and similar chemical class, or any component of the formulation; use in a patient during the acute recovery phase of MI; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either nortriptyline or the MAO inhibitor); initiation of nortriptyline in a patient receiving linezolid or intravenous methylene blue",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F202678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Nortriptyline is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: TCAs may rarely cause bone marrow suppression; monitor for any signs of infection and obtain CBC if symptoms (eg, fever, sore throat) evident.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is low relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is low-moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk of conduction abnormalities with this agent is moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Nortriptyline is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation due to concerns of pro-arrhythmogenesis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. May be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Recommended to discontinue prior to elective surgery requiring general anesthesia. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F202746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F202683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F202709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, tryptophan, SAMe, kava kava (may increase risk of serotonin syndrome and/or excessive sedation).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9465719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies are inconclusive. Nortriptyline and its metabolites cross the human placenta and can be detected in cord blood. According to the manufacturer, the decision to use nortriptyline during pregnancy or in women of childbearing potential should take into account the potential benefits and possible risks. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F202721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9465721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nortriptyline is excreted into breast milk and the M/P ratio ranged from 0.87 to 3.71 in one study. Based on available information, nortriptyline has not been detected in the serum of nursing infants, however low levels of the active metabolite E-10-hydroxynortriptyline have been detected in the serum of newborns following breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F202699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Nortriptyline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $40.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $80.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $145.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $221.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Pamelor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $839.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $839.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $839.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $839.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nortriptyline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (473 mL): $182.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F202687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure and pulse rate (ECG, cardiac monitoring) prior to and during initial therapy in older adults; weight; blood levels are useful for therapeutic monitoring; suicide ideation (especially at the beginning of therapy or when doses are increased or decreased); signs/symptoms of serotonin syndrome",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F202691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Plasma levels do not always correlate with clinical effectiveness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 50-150 ng/mL (SI: 190-570 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;500 ng/mL (SI: &gt;1900 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Allegron (AU, GB, IE);",
"     </li>",
"     <li>",
"      Altilev (UY);",
"     </li>",
"     <li>",
"      Ateben (AR);",
"     </li>",
"     <li>",
"      Aventyl (MY);",
"     </li>",
"     <li>",
"      Martimil (ES);",
"     </li>",
"     <li>",
"      Noritren (DK, EE, FI, IT, NO);",
"     </li>",
"     <li>",
"      Norline (TH);",
"     </li>",
"     <li>",
"      Norpress (NZ);",
"     </li>",
"     <li>",
"      Norterol (PT);",
"     </li>",
"     <li>",
"      Nortrilen (AE, AT, BE, BF, BH, BJ, CH, CI, CY, CZ, DE, EG, ET, GH, GM, GN, GR, HK, ID, IQ, IR, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nortrilin (PK);",
"     </li>",
"     <li>",
"      Nortylin (IL);",
"     </li>",
"     <li>",
"      Nortyline (TH);",
"     </li>",
"     <li>",
"      Ortrip (TH);",
"     </li>",
"     <li>",
"      Pamelor (BR);",
"     </li>",
"     <li>",
"      Paxtibi (ES);",
"     </li>",
"     <li>",
"      Sensaval (SE);",
"     </li>",
"     <li>",
"      Sensival (IN, KP);",
"     </li>",
"     <li>",
"      Vividyl (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F202677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Traditionally believed to increase the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane. However, additional receptor effects have been found including desensitization of adenyl cyclase, down regulation of beta-adrenergic receptors, and down regulation of serotonin receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F202696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic: 1-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 21 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 28-31 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 7-8.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites and small amounts of unchanged drug); feces (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boakes AJ, Laurence DR, Teoh PC, et al, &ldquo;Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1973, 1(5849):311-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/4685619/pubmed\" id=\"4685619\" target=\"_blank\">",
"        4685619",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boehnert MT and Lovejoy FH Jr, &ldquo;Value of the QRS Duration Versus the Serum Drug Level in Predicting Seizures and Ventricular Arrhythmias After an Acute Overdose of Tricyclic Antidepressants,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1985, 313(8):474-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/4022081/pubmed\" id=\"4022081\" target=\"_blank\">",
"        4022081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buchanan J and Zakrzewska J, &ldquo;Burning Mouth Syndrome,&rdquo;",
"      <i>",
"       Clin Evid (online)",
"      </i>",
"      , March 14, 2008. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907957/pdf/2008-1301.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907957/pdf/2008-1301.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/19450321/pubmed\" id=\"19450321\" target=\"_blank\">",
"        19450321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dawling S, Crome P, and Braithwaite R, &ldquo;Pharmacokinetics of Single Oral Doses of Nortriptyline in Depressed Elderly Hospital Patients and Young Healthy Volunteers,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1980, 5(4):394-401.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/6994983/pubmed\" id=\"6994983\" target=\"_blank\">",
"        6994983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frommer DA, Kulig KW, Marx JA, et al, &ldquo;Tricyclic Antidepressant Overdose,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1987, 257(4):521-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/3540330/pubmed\" id=\"3540330\" target=\"_blank\">",
"        3540330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller B, Cooper TB, Chestnut EC, et al, &ldquo;Child and Adolescent Nortriptyline Single Dose Kinetics Predict Steady State Plasma Levels and Suggested Dose: Preliminary Data,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1985, 5(3):154-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/3998205/pubmed\" id=\"3998205\" target=\"_blank\">",
"        3998205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heikkinen T, Ekblad U, and Laine K, &ldquo;Transplacental Transfer of Amitriptyline and Nortriptyline in Isolated Perfused Human Placenta,&rdquo;",
"      <i>",
"       Psychopharmacology (Berl)",
"      </i>",
"      , 2001, 153(4):450-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/11243492/pubmed\" id=\"11243492\" target=\"_blank\">",
"        11243492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larochelle P, Hamet P, and Enjalbert M, &ldquo;Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/376211/pubmed\" id=\"376211\" target=\"_blank\">",
"        376211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HB, Harper CR, and Weinberg WA, &ldquo;A Practical Approach to Children Failing in School,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(4):895-928",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/1635811/pubmed\" id=\"1635811\" target=\"_blank\">",
"        1635811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipper B and Gaynor BD, &ldquo;Value of Serum Tricyclic Antidepressant Levels With Massive Nortriptyline Overdose and Persistent Hypotension,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(1):107.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loughhead AM, Stowe ZN, Newport DJ, et al, &ldquo;Placental Passage of Tricyclic Antidepressants,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 2006, 59(3):287-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/16271264/pubmed\" id=\"16271264\" target=\"_blank\">",
"        16271264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matheson I and Skjaeraasen J, &ldquo;Milk Concentrations of Flupenthixol, Nortriptyline and Zuclopenthixol and Between-Breast Differences in Two Patients,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1988, 35(2):217-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/3191943/pubmed\" id=\"3191943\" target=\"_blank\">",
"        3191943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell JR, Cavanaugh JH, Arias L, et al,  &ldquo;Guanethidine and Related Agents. III Antagonism by Drugs Which Inhibit the Norepinephrine Pump in Man,&rdquo;",
"      <i>",
"       J Clin Invest",
"      </i>",
"      , 1970, 49(8):1596-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/5431666/pubmed\" id=\"5431666\" target=\"_blank\">",
"        5431666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&iacute;nguez Serra MP, Salort Llorca C, Silvestre Donat FJ, \"Pharmacological Treatment of Burning Mouth Syndrome: A Review and Update,\"",
"      <i>",
"       Med Oral Patol Oral Cir Bucal",
"      </i>",
"      , 2007, 12(4):E299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/17664916/pubmed\" id=\"17664916\" target=\"_blank\">",
"        17664916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prince JB, Wilens TE, Biederman J, et al, &ldquo;A Controlled Study of Nortriptyline in Children and Adolescents With Attention Deficit Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 10(3):193-204.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/11052409/pubmed\" id=\"11052409\" target=\"_blank\">",
"        11052409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prochazka AV, Kick S, Steinbrunn C, et al, &ldquo;A Randomized Trial of Nortriptyline Combined With Transdermal Nicotine for Smoking Cessation,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2004, 164(20):2229-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/15534159/pubmed\" id=\"15534159\" target=\"_blank\">",
"        15534159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Glassman AH, Attia E, et al, &ldquo;Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/7977878/pubmed\" id=\"7977878\" target=\"_blank\">",
"        7977878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Laghrissi-Thode F, Kennedy JS, et al, &ldquo;Comparison of Paroxetine and Nortriptyline in Depressed Patients With Ischemic Heart Disease,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(4):287-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/9450712/pubmed\" id=\"9450712\" target=\"_blank\">",
"        9450712",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo;",
"      <i>",
"       Swed Dent J",
"      </i>",
"      , 1985, 9(2):55-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/3925584/pubmed\" id=\"3925584\" target=\"_blank\">",
"        3925584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneider LS, Cooper TB, Staples FR, et al, &ldquo;Prediction of Individual Dosage of Nortriptyline in Depressed Elderly Outpatients,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1987, 7(5):311-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/3680600/pubmed\" id=\"3680600\" target=\"_blank\">",
"        3680600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sunderrajan S, Brooks CS, and Sunderrajan EV, &ldquo;Nortriptyline-Induced Severe Hyperventilation,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1985, 145(4):746-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/3985739/pubmed\" id=\"3985739\" target=\"_blank\">",
"        3985739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Svedmyr N, &ldquo;The Influence of a Tricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Noradrenaline and Adrenalin in Man,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1968, 7(1):77-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/5636628/pubmed\" id=\"5636628\" target=\"_blank\">",
"        5636628",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      GF and Young MJ, &ldquo;Criteria for Admitting Patients With Tricyclic Antidepressant Overdose,&rdquo;",
"      <i>",
"       J emerge Med",
"      </i>",
"      , 1988, 6(2):121-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/3385173/pubmed\" id=\"3385173\" target=\"_blank\">",
"        3385173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      turbot J, Norman TR, Burrows GD, et al, &ldquo;Pharmacokinetics of Nortriptyline in Elderly Volunteers,&rdquo;",
"      <i>",
"       commune",
"      </i>",
"      , 1980, 4(3):225-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/7226754/pubmed\" id=\"7226754\" target=\"_blank\">",
"        7226754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wisner KL and Perl JM, &ldquo;Serum Nortriptyline Levels in Nursing Mothers and Their Infants,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1991, 148(9):1234-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/1883004/pubmed\" id=\"1883004\" target=\"_blank\">",
"        1883004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, wiser KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       upstate canicola",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/21/30040/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9711 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30040=[""].join("\n");
var outline_f29_21_30040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709176\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202713\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202714\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202751\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202717\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202732\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202718\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202719\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202690\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202674\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874747\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202694\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202748\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202760\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202749\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202697\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202678\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202746\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202683\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202709\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9465719\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202721\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9465721\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202699\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202687\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202691\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038709\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202677\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202696\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9711\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9711|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/22/25957?source=related_link\">",
"      Nortriptyline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/26/38310?source=related_link\">",
"      Nortriptyline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_21_30041="Outcome of sudden cardiac arrest";
var content_f29_21_30041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Outcome of sudden cardiac arrest",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/21/30041/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30041/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30041/contributors\">",
"     Jie Cheng, MD, PhD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/21/30041/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30041/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30041/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/21/30041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30041/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/21/30041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden cessation of cardiac mechanical activity with hemodynamic collapse, most frequently due to sustained ventricular",
"    <span class=\"nowrap\">",
"     tachycardia/ventricular",
"    </span>",
"    fibrillation. These events mostly occur in patients with structural heart disease (that may not have been previously diagnosed), particularly coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The event is referred to as SCA (or aborted SCD) if an intervention (eg, defibrillation) or spontaneous reversion restores circulation. The event is called SCD if the patient dies. However, the use of SCD to describe both fatal and nonfatal cardiac arrest persists by convention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of patients following SCA will be reviewed here. The issues related to acute therapy for SCA, including guidelines for advanced cardiovascular life support (ACLS), and issues related to prevention of recurrent sudden cardiac death, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS FOLLOWING SUDDEN CARDIAC ARREST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in the treatment of heart disease, the outcome of patients experiencing SCA remains poor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A report analyzed outcomes for over 12,000 patients treated by emergency medical services (EMS) personnel in Seattle over 24 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1\">",
"     1",
"    </a>",
"    ]. Survival to hospital discharge for those treated between 1998 and 2001 was not significantly better than for those treated between 1977 and 1981 (15.7 versus 17.5 percent). In contrast, the long-term outcome among patients who survive until hospital discharge following SCA appears to be improving [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/4\">",
"     4",
"    </a>",
"    ]. Among a nationwide cohort of 547,153 patients in Japan with out-of-hospital SCA between 2005 and 2009, survival to hospital discharge with favorable neurologic status improved approximately twofold in several groups over the five-year period (from 1.6 to 2.8 percent among all patients with out-of-hospital SCA, from 2.1 to 4.3 percent among bystander-witnessed SCA, and from 9.8 to 20.6 percent among bystander-witnessed SCA with ventricular fibrillation as the initial rhythm) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/5\">",
"     5",
"    </a>",
"    ]. However, in spite of this doubling of neurologically favorable survival, overall survival following SCA remains poor.",
"   </p>",
"   <p>",
"    The reasons for the continued poor survival of patients with SCA are not certain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1\">",
"     1",
"    </a>",
"    ]. Although some aspects of acute resuscitation have improved over time (increased bystander cardiopulmonary resuscitation (CPR) and shortened time to defibrillation), these positive trends have been off-set by adverse trends in clinical features of patients presenting with SCA (such as increasing age and decreasing proportion presenting with ventricular fibrillation) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. In addition, the response times of both basic life support (BLS) and advanced life support (ALS) services have increased, possibly as a result of population growth and urbanization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Marked regional differences in the incidence and outcome of SCA have been observed. In a prospective observational study of 10 North American regions, the adjusted incidence of EMS-treated out of hospital SCA ranged from 40.3 to 86.7 (median 52.1) per 100,000 census population; known survival to discharge ranged from 3.0 to 16.3 percent (median 8.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/8\">",
"     8",
"    </a>",
"    ]. The adjusted incidence of ventricular fibrillation ranged from 9.3 to 19.0 (median 12.6) per 100,000 census population; known survival to discharge ranged from 7.7 to 39.9 (median 22) percent. These regional differences highlight the importance of local health care and EMS systems to SCA outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OUTCOME ACCORDING TO ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an association between the mechanism of SCA and the outcome of initial resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Asystole",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the initial rhythm is asystole, the likelihood of successful resuscitation is low. Only 10 percent of patients with out-of-hospital arrests and initial asystole survive until hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] and only 0 to 2 percent until hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The poor outcome in patients with asystole or bradycardia due to a very slow idioventricular rhythm probably reflects the prolonged duration of the cardiac arrest (usually more than four minutes) and the presence of severe, irreversible myocardial damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors associated with successful resuscitation of patients presenting with asystole include witnessed arrest, younger patient age, shorter time to arrival of EMS personnel, and no further need for treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    for a bradyarrhythmia after initial resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/10,12\">",
"     10,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pulseless electrical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have SCA due to pulseless electrical activity (PEA) (also called electrical-mechanical dissociation) also have a poor outcome. In one study of 150 such patients, 23 percent were resuscitated and survived to hospital admission; only 11 percent survived until hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ventricular tachyarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome is much better when the initial rhythm is a sustained ventricular tachyarrhythmia. The most frequent etiology is ventricular fibrillation (VF). Approximately 25 to 40 percent of patients with SCA caused by VF survive until hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1,14,15\">",
"     1,14,15",
"    </a>",
"    ]. In the Seattle series cited above of over 12,000 EMS-treated patients with SCA, 38 percent had witnessed VF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with witnessed VF had a significantly greater likelihood of surviving to hospital discharge than those with other rhythms (34 versus 6 percent).",
"   </p>",
"   <p>",
"    Acute myocardial infarction (MI) is the underlying cause of VF in many of the patients who survive to hospital discharge. In a series of 79 such patients from the Mayo Clinic, 47 percent had an acute MI, while in a series of 47 such patients from the Netherlands, 51 percent had an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival is approximately 65 to 70 percent in patients who present with hemodynamically unstable ventricular tachycardia (VT) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/16\">",
"     16",
"    </a>",
"    ]. The prognosis may be better in patients found in monomorphic VT because of the potential for some systemic perfusion during this more organized arrhythmia. In addition, patients with VT tend to have a lower incidence of a previous infarction and a higher ejection fraction when compared to those with VF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594215622\">",
"    <span class=\"h2\">",
"     SCA due to noncardiac causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as one-third of cases of SCA are due to noncardiac causes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Trauma, nontraumatic bleeding, intoxication, near drowning, and pulmonary embolism are the most common noncardiac etiologies. In one series, 40 percent of such patients were successfully resuscitated and hospitalized; however, only 11 percent were discharged from the hospital and only 6 percent were neurologically intact or had mild disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING OUT-OF-HOSPITAL SCA OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the efforts of emergency personnel, resuscitation from out-of-hospital SCA is successful in only one-third of patients, and only about 10 percent of all patients are ultimately discharged from the hospital, many of whom are neurologically impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/2,3,6,19-23\">",
"     2,3,6,19-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cause of death in-hospital is most often noncardiac, usually anoxic encephalopathy or respiratory complications from long-term ventilator dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/24\">",
"     24",
"    </a>",
"    ]. Only about 10 percent of patients die primarily from recurrent arrhythmia, while approximately 30 percent die primarily from a low cardiac output or cardiogenic shock as the consequence of mechanical failure. Recurrence of severe arrhythmia in the hospital is associated with a worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to later initiation of CPR and the presence of asystole or pulseless electrical activity (electromechanical dissociation) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/9-11,13\">",
"     9-11,13",
"    </a>",
"    ], there are a number of other factors that are associated with a poor outcome following out-of-hospital SCA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/15,26-29\">",
"     15,26-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of any vital signs",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Cerebrovascular accident with severe neurologic deficit",
"     </li>",
"     <li>",
"      Cancer or Alzheimer disease",
"     </li>",
"     <li>",
"      History of more than two chronic diseases",
"     </li>",
"     <li>",
"      A history of cardiac disease",
"     </li>",
"     <li>",
"      Prolonged CPR more than five minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also several poor prognostic features in patients with SCA who survive until admission:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent coma after CPR (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link\">",
"       \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypotension, pneumonia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal failure after CPR",
"     </li>",
"     <li>",
"      Need for intubation or pressors",
"     </li>",
"     <li>",
"      Class III or IV heart failure",
"     </li>",
"     <li>",
"      Older age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     VF duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;VF in the human heart rarely, if ever terminates spontaneously, and survival is therefore dependent upon the prompt delivery of effective CPR. Electrical defibrillation is the",
"    <strong>",
"     only",
"    </strong>",
"    way to reestablish organized electrical activity and myocardial contraction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"     \"Cardioversion for specific arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increasing duration of VF has two major adverse effects: it reduces the ability to terminate the arrhythmia and, if VF continues for more than four minutes, there is irreversible damage to the central nervous system and other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. As a result, the longer the duration of the cardiac arrest, the lower the likelihood of resuscitation or survival with or without neurologic impairment even if CPR is successful. It has been suggested that without CPR, survival from a cardiac arrest caused by VF declines by approximately 10 percent for each minute without defibrillation, and after more than 12 minutes the survival rate is only 2 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Time to resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;These observations constitute the rationale for attempts to provide more rapid resuscitation in patients with out-of-hospital SCA. One approach is optimizing the EMS system within a community to reduce the response interval to within eight minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, as noted above, the response times of both BLS and ALS services have actually increased, possibly as a result of population growth and urbanization. In the Seattle series of over 12,000 EMS-treated patients, the BLS response interval increased from 3.8 to 5.1 minutes between 1977 and 2001, and the ALS response interval increased from 8.4 to 9.0 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, bystander CPR and even defibrillation have been recommended and have been implemented in some settings. Such interventions permit more rapid responses than those provided by ALS or BLS personnel, with better survival as a result. In the Seattle series, the odds ratio for survival to discharge for patients who received bystander CPR to those who did not was 1.85 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bystander CPR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of CPR by a layperson bystander (bystander CPR or bystander-initiated CPR) is an important factor in determining patient outcome after out-of-hospital sudden cardiac arrest. As described in more detail below, survival after sudden cardiac arrest is higher among those who have bystander CPR when compared with those who initially receive CPR from EMS personnel. In addition to improved survival, early restoration or improvement in circulation is associated with better neurologic function among survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For adults with sudden out-of-hospital cardiac arrest, compression-only bystander CPR (without rescue breathing) appears to have equal or possibly greater efficacy compared with standard bystander CPR (compressions plus rescue breathing). The 2010 American Heart Association (AHA) Guidelines for CPR recommended that bystanders perform compression-only CPR to provide high-quality chest compressions prior to the arrival of emergency personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H93796253\">",
"     'Chest compression-only CPR'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The importance of bystander CPR and support for compression-only bystander CPR comes from a combination of retrospective and prospective studies. An initial report from the Seattle Heart Watch program evaluated 109 consecutive patients resuscitated at the scene by a bystander trained in CPR and compared their outcomes with those of 207 patients who initially received CPR from EMS personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/40\">",
"     40",
"    </a>",
"    ]. There was no difference between the two groups in the percentage of patients resuscitated at the scene and admitted alive to the hospital (67 versus 61 percent), but the percentage discharged alive was significantly higher among those with bystander CPR (43 versus 22 percent). The most important reason for the improvement in survival in this study was that earlier CPR and prompt defibrillation were associated with less damage to the central nervous system. More patients with bystander CPR were conscious at the time of hospital admission (50 versus 9 percent), and more regained consciousness by the end of hospitalization (81 versus 52 percent).",
"   </p>",
"   <p>",
"    These observations were subsequently confirmed in larger studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In a trial evaluating the efficacy of prehospital ACLS interventions in 5638 patients with cardiac arrest (VF, PEA, or asystole), 286 (5 percent) survived to hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/41\">",
"     41",
"    </a>",
"    ]. Bystander CPR significantly increased the likelihood of survival (adjusted odds ratio 3.7, 95% CI 2.5-5.4). Other factors associated with a higher likelihood of survival include lower age and shorter intervals between collapse, CPR, and defibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the benefits of bystander CPR, it is not always performed. Reasons for this include the bystander&rsquo;s lack of CPR training and concerns about possible transmission of disease while performing rescue breathing. Neighborhood demographics (racial composition and income level) also appear to be a factor in the rates of bystander CPR performance. In an analysis of 14,225 patients with cardiac arrest in 29 US sites participating in Cardiac Arrest Registry to Enhance Survival (CARES), bystander CPR was significantly more likely to be performed in higher-income (above 40,000 USD per year), predominantly (&gt;80 percent) white neighborhoods than in higher-income, predominantly (&gt;80 percent) black neighborhoods or lower-income (less than 40,000 USD per year) neighborhoods of any racial mix (mostly white, mostly black, or integrated) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interventions that appear to improve the rate of bystander CPR include verbal encouragement and instruction in CPR by EMS dispatchers, and public campaigns to promote the delivery of bystander CPR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of over 12,000 EMS-treated patients from Seattle, bystanders not trained in CPR were given instructions by telephone from the EMS dispatcher [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1\">",
"       1",
"      </a>",
"      ]. The proportion of patients receiving bystander CPR increased from 27 to 50 percent, almost entirely as a result of the implementation of dispatcher-assisted CPR in that interval.",
"     </li>",
"     <li>",
"      A prospective observational study of 4400 adults with out-of-hospital sudden cardiac death noted a rise in the delivery of bystander CPR from 28 to 40 percent over the course of a five-year public campaign to encourage bystander compression-only CPR [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93796253\">",
"    <span class=\"h4\">",
"     Chest compression-only CPR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial observational studies that evaluated the delivery of compression-only CPR versus standard CPR including rescue breathing found no significant differences in survival or long-term neurologic function between the two groups, suggesting that compression-only CPR could be safely delivered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Three randomized trials of compression-only CPR versus standard CPR all showed a trend toward improved outcomes in the compression-only CPR group [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The trends toward improved survival to discharge with compression-only CPR became statistically significant when the results of the three trials (thereby increasing the number of patients) were combined in a meta-analysis (14 percent versus 12 percent in the standard CPR group; risk ratio 1.22, 95% CI 1.01 to 1.46) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. This finding holds promise for improving the delivery of bystander CPR. Further data are required to determine if bystander-delivered compression-only CPR (rather than standard CPR) will translate into better neurologic outcomes for patients with out-of-hospital cardiac arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Timing of defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard of care for resuscitation from ventricular fibrillation has been defibrillation as soon as possible. In the Seattle series of over 12,000 EMS-treated patients, 4546 had witnessed VF. For these patients, the defibrillation response interval was significantly correlated with survival to hospital discharge (odds ratio 0.88 for every one-minute increase in response time) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent studies have shown similar benefits, with earlier defibrillation being associated with improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/41,54\">",
"     41,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these findings, it has been suggested that outcomes may be improved by performing CPR",
"    <strong>",
"     before",
"    </strong>",
"    defibrillation, at least in patients in whom defibrillation is delayed for more than four to five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. An initial report from Seattle compared outcomes in two time periods: when an initial shock was given as soon as possible; and, subsequently, when the initial shock was delayed until 90 seconds of CPR had been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/55\">",
"     55",
"    </a>",
"    ]. Survival to hospital discharge was significantly increased with routine CPR before defibrillation, primarily in patients in whom the initial response interval was four minutes or longer (27 versus 17 percent without prior CPR).",
"   </p>",
"   <p>",
"    However, in the largest study to date comparing shorter versus longer periods of initial CPR prior to defibrillation in 9933 patients with sudden cardiac arrest, patients were randomly assigned to receive 30 to 60 seconds versus 180 seconds of CPR prior to cardiac rhythm analysis and defibrillation (if indicated) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/57\">",
"     57",
"    </a>",
"    ]. There was no significant difference in the primary endpoint of survival to hospital discharge with satisfactory functional status (5.9 percent in both groups).",
"   </p>",
"   <p>",
"    For patients with sudden cardiac arrest and ventricular arrhythmia, we perform early defibrillation and CPR as recommended in the 2010 ACLS guidelines (",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Automated external defibrillators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of automated external defibrillators (AEDs) by early responders is another approach to more rapid resuscitation. In most but not all studies, AEDs have been found to improve survival after out of hospital cardiac arrest. The development, use, allocation, and efficacy of AEDs are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=see_link\">",
"     \"Automated external defibrillators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Predictive value of BLS and ALS rules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The OPALS study group has proposed two termination of resuscitation rules for use by EMS personnel. The rule for BLS providers equipped with AEDs includes the following three criteria: (1) event not witnessed by emergency medical services personnel, (2) no AED used or manual shock applied in out of hospital setting, and (3) no return of spontaneous circulation in out of hospital setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/58\">",
"     58",
"    </a>",
"    ]. The advanced life support (ALS) rule includes the BLS criteria as well as two additional criteria: (1) arrest not witnessed by bystander and (2) no bystander-administered CPR [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Validation of the predictive value of the BLS and ALS termination rules was performed with data from a retrospective cohort study that included 5505 adults with out of hospital SCA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/60\">",
"     60",
"    </a>",
"    ]. The overall rate of survival to hospital discharge was 7 percent. Of 2592 patients (47 percent) who met BLS criteria for termination of resuscitation efforts, only 5 survived to hospital discharge. Of 1192 patients (22 percent) who met ALS criteria, none survived to hospital discharge.",
"   </p>",
"   <p>",
"    However, the validity of these termination rules may be reduced with improvements in EMS and postresuscitation care. One potential target for understanding and ameliorating current limitations to post-arrest care is the observed marked regional variation in prognosis following SCA. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prognosis following sudden cardiac arrest'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adequacy of CPR",
"    </span>",
"    &nbsp;&mdash;&nbsp;End-tidal carbon dioxide levels have an excellent correlation with very low cardiac outputs when measured after at least 10 minutes of CPR, and may provide prognostic information. In one study, for example, an end-tidal carbon dioxide level &le;10 mmHg, measured after 20 minutes of standard CPR, identified individuals who did not survive to hospitalization discharge with a sensitivity and specificity of 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/13\">",
"     13",
"    </a>",
"    ]. Survivors had a much higher end-tidal carbon dioxide concentration at 20 minutes of CPR than nonsurvivors (32.8 versus 4.4 mmHg). These observations suggest that the cardiac output maintained during CPR is a determinant of outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link&amp;anchor=H7#H7\">",
"     \"Carbon dioxide monitoring (capnography)\", section on 'Effectiveness of CPR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2010 AHA Guidelines recommend a rate of at least 100 chest compressions per minute. In a study of 3098 patients with out-of-hospital cardiac arrest, return of spontaneous circulation was highest at a rate of 125 compressions per minute [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/61\">",
"     61",
"    </a>",
"    ]. However, higher chest compression rates were not significantly associated with survival to hospital discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H6#H6\">",
"     \"Basic life support (BLS) in adults\", section on 'Performance of excellent chest compressions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Body temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in body temperature is associated with unfavorable functional neurologic recovery after successful CPR. The increase in temperature may be neurally-mediated and can exacerbate the degree of neural injury associated with brain ischemia. For the highest temperature within 48 hours, each degree Celsius higher than 37&ordm;C increases the risk of an unfavorable neurologic recovery (odds ratio of 2.26 in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, the induction of mild to moderate hypothermia (target temperature 32 to 34&ordm;C for 24 hours) may be beneficial in patients successfully resuscitated after a cardiac arrest. Improved neurologic outcome and reduced mortality has been demonstrated in series of patients with VF arrest in whom spontaneous circulation was restored, even when the patient remains comatose after resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=see_link&amp;anchor=H9724176#H9724176\">",
"     \"Post-cardiac arrest management in adults\", section on 'Therapeutic (Induced) hypothermia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prehospital ACLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incremental benefit of deploying EMS personnel trained in ACLS interventions (intubation, insertion of intravenous lines, and intravenous medication administration) on survival after cardiac arrest probably depends upon the quality of other prehospital services.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the OPALS study, ACLS interventions were added to an optimized emergency medical services program of rapid defibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/41\">",
"       41",
"      </a>",
"      ]. No improvement in the rate of survival for out of hospital cardiac arrest was observed with addition of an ACLS program.",
"     </li>",
"     <li>",
"      In a retrospective report from Queensland with an emergency services program not optimized for early defibrillation, the presence of ACLS-skilled EMS personnel was associated with improved survival for out of hospital cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Effect of older age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of SCA increases with age, and older age has been associated with a poorer survival in some, but not all studies of out-of-hospital cardiac arrests [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1,64-67\">",
"     1,64-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 5882 patients who experienced an out-of-hospital cardiac arrest, 22 percent were &gt;80 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/68\">",
"       68",
"      </a>",
"      ]. Compared to patients &lt;80 years of age, octogenarians and nonagenarians had a lower rate of hospital discharge (9.4 and 4.4 versus 19 percent for those &lt;80). The discharge rate was higher in those with VF or pulseless VT as the initial rhythm. Very old patients still had a poorer survival (24 and 17 versus 36 percent), but age was a weaker predictor than the initial rhythm.",
"     </li>",
"     <li>",
"      In the Seattle series of over 12,000 EMS-treated patients, every one-year increase in age was associated with a lower likelihood of survival to hospital discharge for all patients (odds ratio 0.97 per year) and for those with witnessed VF (odds ratio 0.98 per year) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Effect of gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of SCA is greater in men than women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/1,69\">",
"     1,69",
"    </a>",
"    ]. The effect of gender on outcome has been examined in multiple cohorts, with the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men are more likely than women to have ventricular fibrillation (VF) or ventricular tachycardia (VT) as an initial rhythm.",
"     </li>",
"     <li>",
"      Men are more likely than women to have a witnessed arrest.",
"     </li>",
"     <li>",
"      Men have a higher one-month survival than women following SCA, due to the higher likelihood of",
"      <span class=\"nowrap\">",
"       VF/VT",
"      </span>",
"      as their presenting rhythm. However, when considering only patients with",
"      <span class=\"nowrap\">",
"       VF/VT",
"      </span>",
"      as the initial rhythm, women have a greater survival with favorable neurologic outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Effect of comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of preexisting chronic conditions on the outcome of out-of-hospital SCA was evaluated in a series of 1043 SCA victims in King County, Washington in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/71\">",
"     71",
"    </a>",
"    ]. There was a statistically significant reduction in the probability of survival to hospital discharge with increasing numbers of chronic conditions, such as congestive heart failure, prior myocardial infarction, hypertension, and diabetes (OR 0.84 for each additional chronic condition). The impact of comorbidities was more prominent with longer EMS response intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING IN-HOSPITAL SCA OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of patients who experience SCA in the hospital is poor, with reported survival to hospital discharge rates of 6 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. In the largest cohort of 64,339 patients at 435 hospitals who had in-hospital SCA and underwent standard resuscitation procedures, 49 percent of patients had return of spontaneous circulation, with 15 percent overall survival to hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several clinical factors have been identified that predict a greater likelihood of survival to hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/72,75\">",
"     72,75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Witnessed arrest",
"     </li>",
"     <li>",
"      VT or VF as initial rhythm",
"     </li>",
"     <li>",
"      Pulse regained during first 10 minutes of CPR",
"     </li>",
"     <li>",
"      Longer duration of overall resuscitation efforts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Delays in providing initial defibrillation have been associated with worse outcomes. This was illustrated in a report of 6789 patients with in-hospital SCA due to VT or VF from 369 hospitals participating in the National Registry of Cardiopulmonary Resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/76\">",
"     76",
"    </a>",
"    ]. Delayed defibrillation (more than two minutes after SCA) occurred in 30 percent of patients and was associated with a significantly lower probability of surviving to hospital discharge (22.2 percent versus 39.3 percent). Delayed defibrillation was more common with black race, noncardiac admitting diagnosis, cardiac arrest at a hospital with fewer than 250 beds, an unmonitored hospital unit, and arrest during after-hours periods.",
"   </p>",
"   <p>",
"    Survival following in-hospital SCA treated with an automated external defibrillator (AED) has also been evaluated using data derived from the National Registry of Cardiopulmonary Resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/77\">",
"     77",
"    </a>",
"    ]. When compared to usual resuscitative care, the use of an AED did not improve survival among patients with a shockable rhythm and was associated with a lower survival to hospital discharge among patients with a non-shockable rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=see_link&amp;anchor=H13#H13\">",
"     \"Automated external defibrillators\", section on 'In-hospital AED allocation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     IMPACT OF ARTERIAL OXYGEN LEVEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial hyperoxia early after SCA may have deleterious effects, perhaps due to oxidative injury. The 2008 International Liaison Committee on Resuscitation cited preclinical evidence of harm from hyperoxia and suggested a goal arterial oxygenation of 94 to 96 percent post SCA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study to examine this issue was performed using a multicenter database including 6326 patients with arterial blood gas analysis within 24 hours after ICU arrival following cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/79\">",
"     79",
"    </a>",
"    ]. The study included patients with in-hospital and out-of-hospital SCA (57 percent were hospital inpatients and 43 percent were from the emergency department). Oxygenation status was categorized according to the first ICU arterial blood gas value, with hyperoxia defined as PaO2 &ge;300 mmHg, hypoxia as PaO2 &lt;60 mmHg, and the remaining as normoxia. The majority of patients had hypoxia (63 percent) with similar numbers having hyperoxia (18 percent) and normoxia (19 percent). The hyperoxia group had higher in-hospital mortality compared with the normoxia and the hypoxia groups (63 percent versus 45 percent and 57 percent). In a multivariable model, hyperoxia was an independent risk factor for death (OR 1.8; 95% CI, 1.5-2.2). Hypoxia was also an independent risk factor (OR 1.3; 95% CI, 1.1-1.5). Further data are needed to determine the impact of oxygen titration during and after resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported long-term outcome of survivors of SCD is variable and may depend upon multiple factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with out-of-hospital VF, was early defibrillation achieved?",
"     </li>",
"     <li>",
"      Do the data come from randomized trials, in which many, often sicker, patients are excluded, or from community-based observations?",
"     </li>",
"     <li>",
"      Was the patient treated with antiarrhythmic drugs or an implantable cardioverter-defibrillator (ICD)?",
"     </li>",
"     <li>",
"      Does the patient have other risk factors, particularly a reduced left ventricular ejection fraction (LVEF)?",
"     </li>",
"     <li>",
"      Do patients with seemingly transient or reversible causes of SCA have a better prognosis?",
"     </li>",
"     <li>",
"      Did the patient have VF or VT during the initial episode?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential effect of successful early defibrillation on long-term outcome following out-of-hospital cardiac arrest due to VF was assessed in a population-based study of 200 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30041/abstract/80\">",
"     80",
"    </a>",
"    ]. Over 70 percent of these patients survived until hospital admission, and 40 percent of these patients were discharged with mild or absent neurologic impairment. Among these 79 patients, 43 underwent coronary revascularization and 35 received an ICD, 13 of whom had subsequent appropriate shocks. The expected five-year survival of the study population (79 percent) was the same as that of age-, sex-, and disease-matched controls who did not have out-of-hospital cardiac arrest, but significantly lower than age- and sex-matched controls in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"       \"Patient information: Sudden cardiac arrest (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30436139\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite advances in the treatment of heart disease, the outcome of patients experiencing sudden cardiac arrest (SCA) remains poor. The reasons for the continued poor outcomes are likely multifactorial (eg, delayed bystander cardiopulmonary resuscitation [CPR], delayed defibrillation, advanced age, decreased proportion presenting with ventricular fibrillation). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis following sudden cardiac arrest'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is an association between the mechanism of SCA and the outcome of initial resuscitation, with better survival in patients presenting with a ventricular tachyarrhythmia compared to those with asystole or pulseless electrical activity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Outcome according to etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among the many factors that appear to have an influence on the outcome of SCA, the elapsed time prior to effective resuscitation (ie, establishment of an effective pulse) appears to be the most critical element. There are several ways to decrease the time to the onset of resuscitative efforts:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rapid Emergency Medical System response &ndash; Optimizing the EMS system within a community to reduce the response interval to eight minutes or less has been proposed as a way to improve the outcomes of SCA. However, due to a variety of factors, EMS response time of eight minutes or less cannot always be achieved. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Time to resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bystander CPR &ndash; The administration of CPR by a layperson bystander (bystander CPR) is an important factor in determining patient outcome after out-of-hospital SCA, as early restoration or improvement in circulation has been shown to result in greater survival and better neurologic function among survivors. Bystander CPR, however, is not always performed, primarily due to the bystander&rsquo;s lack of CPR training",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      concerns about possible transmission of disease while performing rescue breathing. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Bystander CPR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early defibrillation &ndash; The standard of care for resuscitation of SCA has been defibrillation as soon as possible when indicated. Shorter defibrillation response intervals correlate with greater survival to hospital discharge. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Timing of defibrillation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"       \"Advanced cardiac life support (ACLS) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Automated external defibrillators &ndash; The use of automated external defibrillators (AEDs) by early responders is another approach to more rapid resuscitation. In most, but not all studies, AEDs have been found to improve survival after out-of-hospital cardiac arrest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=see_link\">",
"       \"Automated external defibrillators\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several observational studies evaluating compression-only CPR versus standard CPR including rescue breathing reported no significant differences in survival or long-term neurologic function between the two groups, suggesting that compression-only CPR could be safely delivered. Three randomized trials of compression-only CPR versus standard CPR have all shown a trend toward improved outcomes in the compression-only CPR group, and a 2010 meta-analysis of the three randomized trials reported an increased survival to hospital discharge among patients who received compression-only CPR. As such, if a sole bystander is present or multiple bystanders are reluctant to perform mouth-to-mouth ventilation, we encourage the performance of CPR using chest compressions only. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Bystander CPR'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H5#H5\">",
"       \"Basic life support (BLS) in adults\", section on 'Chest compressions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The induction of mild to moderate hypothermia (target temperature 32 to 34&ordm;C for 24 hours) may be beneficial in patients successfully resuscitated after a cardiac arrest. Improved neurologic outcome and reduced mortality has been demonstrated in series of patients with VF arrest in whom spontaneous circulation was restored, even when the patient remains comatose after resuscitation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link&amp;anchor=H7#H7\">",
"       \"Hypoxic-ischemic brain injury: Evaluation and prognosis\", section on 'Therapeutic (induced) hypothermia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/1\">",
"      Rea TD, Eisenberg MS, Becker LJ, et al. Temporal trends in sudden cardiac arrest: a 25-year emergency medical services perspective. Circulation 2003; 107:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/2\">",
"      de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/3\">",
"      de Vos R, de Haes HC, Koster RW, de Haan RJ. Quality of survival after cardiopulmonary resuscitation. Arch Intern Med 1999; 159:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/4\">",
"      Rea TD, Crouthamel M, Eisenberg MS, et al. Temporal patterns in long-term survival after resuscitation from out-of-hospital cardiac arrest. Circulation 2003; 108:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/5\">",
"      Kitamura T, Iwami T, Kawamura T, et al. Nationwide improvements in survival from out-of-hospital cardiac arrest in Japan. Circulation 2012; 126:2834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/6\">",
"      Herlitz J, Andersson E, B&aring;ng A, et al. Experiences from treatment of out-of-hospital cardiac arrest during 17 years in G&ouml;teborg. Eur Heart J 2000; 21:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/7\">",
"      Eckstein M, Stratton SJ, Chan LS. Cardiac Arrest Resuscitation Evaluation in Los Angeles: CARE-LA. Ann Emerg Med 2005; 45:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/8\">",
"      Nichol G, Thomas E, Callaway CW, et al. Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA 2008; 300:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/9\">",
"      Weaver WD, Cobb LA, Hallstrom AP, et al. Factors influencing survival after out-of-hospital cardiac arrest. J Am Coll Cardiol 1986; 7:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/10\">",
"      Engdahl J, B&aring;ng A, Lindqvist J, Herlitz J. Can we define patients with no and those with some chance of survival when found in asystole out of hospital? Am J Cardiol 2000; 86:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/11\">",
"      Gray WA, Capone RJ, Most AS. Unsuccessful emergency medical resuscitation--are continued efforts in the emergency department justified? N Engl J Med 1991; 325:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/12\">",
"      Myerburg RJ, Estes D, Zaman L, et al. Outcome of resuscitation from bradyarrhythmic or asystolic prehospital cardiac arrest. J Am Coll Cardiol 1984; 4:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/13\">",
"      Levine RL, Wayne MA, Miller CC. End-tidal carbon dioxide and outcome of out-of-hospital cardiac arrest. N Engl J Med 1997; 337:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/14\">",
"      Bunch TJ, White RD, Gersh BJ, et al. Outcomes and in-hospital treatment of out-of-hospital cardiac arrest patients resuscitated from ventricular fibrillation by early defibrillation. Mayo Clin Proc 2004; 79:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/15\">",
"      de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Circumstances and causes of out-of-hospital cardiac arrest in sudden death survivors. Heart 1998; 79:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/16\">",
"      Goldstein S, Landis JR, Leighton R, et al. Characteristics of the resuscitated out-of-hospital cardiac arrest victim with coronary heart disease. Circulation 1981; 64:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/17\">",
"      Adhar GC, Larson LW, Bardy GH, Greene HL. Sustained ventricular arrhythmias: differences between survivors of cardiac arrest and patients with recurrent sustained ventricular tachycardia. J Am Coll Cardiol 1988; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/18\">",
"      Kuisma M, Alasp&auml;&auml; A. Out-of-hospital cardiac arrests of non-cardiac origin. Epidemiology and outcome. Eur Heart J 1997; 18:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/19\">",
"      Liberthson RR, Nagel EL, Hirschman JC, Nussenfeld SR. Prehospital ventricular defibrillation. Prognosis and follow-up course. N Engl J Med 1974; 291:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/20\">",
"      Taffet GE, Teasdale TA, Luchi RJ. In-hospital cardiopulmonary resuscitation. JAMA 1988; 260:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/21\">",
"      Bedell SE, Delbanco TL, Cook EF, Epstein FH. Survival after cardiopulmonary resuscitation in the hospital. N Engl J Med 1983; 309:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/22\">",
"      Murphy DJ, Murray AM, Robinson BE, Campion EW. Outcomes of cardiopulmonary resuscitation in the elderly. Ann Intern Med 1989; 111:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/23\">",
"      Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002; 346:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/24\">",
"      Myerburg RJ, Conde CA, Sung RJ, et al. Clinical, electrophysiologic and hemodynamic profile of patients resuscitated from prehospital cardiac arrest. Am J Med 1980; 68:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/25\">",
"      Myerburg RJ, Kessler KM, Zaman L, et al. Survivors of prehospital cardiac arrest. JAMA 1982; 247:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/26\">",
"      Greene HL. Sudden arrhythmic cardiac death--mechanisms, resuscitation and classification: the Seattle perspective. Am J Cardiol 1990; 65:4B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/27\">",
"      Marwick TH, Case CC, Siskind V, Woodhouse SP. Prediction of survival from resuscitation: a prognostic index derived from multivariate logistic model analysis. Resuscitation 1991; 22:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/28\">",
"      Herlitz J, Eek M, Holmberg M, et al. Characteristics and outcome among patients having out of hospital cardiac arrest at home compared with elsewhere. Heart 2002; 88:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/29\">",
"      Rea TD, Paredes VL. Quality of life and prognosis among survivors of out-of-hospital cardiac arrest. Curr Opin Crit Care 2004; 10:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/30\">",
"      Niemann JT, Cairns CB, Sharma J, Lewis RJ. Treatment of prolonged ventricular fibrillation. Immediate countershock versus high-dose epinephrine and CPR preceding countershock. Circulation 1992; 85:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/31\">",
"      Baum RS, Alvarez H 3rd, Cobb LA. Survival after resuscitation from out-of-hospital ventricular fibrillation. Circulation 1974; 50:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/32\">",
"      Olson DW, LaRochelle J, Fark D, et al. EMT-defibrillation: the Wisconsin experience. Ann Emerg Med 1989; 18:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/33\">",
"      Callans DJ. Out-of-hospital cardiac arrest--the solution is shocking. N Engl J Med 2004; 351:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/34\">",
"      Eisenberg MS, Horwood BT, Cummins RO, et al. Cardiac arrest and resuscitation: a tale of 29 cities. Ann Emerg Med 1990; 19:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/35\">",
"      Thompson RJ, McCullough PA, Kahn JK, O'Neill WW. Prediction of death and neurologic outcome in the emergency department in out-of-hospital cardiac arrest survivors. Am J Cardiol 1998; 81:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/36\">",
"      Stiell IG, Wells GA, Field BJ, et al. Improved out-of-hospital cardiac arrest survival through the inexpensive optimization of an existing defibrillation program: OPALS study phase II. Ontario Prehospital Advanced Life Support. JAMA 1999; 281:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/37\">",
"      Aufderheide TP, Yannopoulos D, Lick CJ, et al. Implementing the 2005 American Heart Association Guidelines improves outcomes after out-of-hospital cardiac arrest. Heart Rhythm 2010; 7:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/38\">",
"      Sayre MR, Berg RA, Cave DM, et al. Hands-only (compression-only) cardiopulmonary resuscitation: a call to action for bystander response to adults who experience out-of-hospital sudden cardiac arrest: a science advisory for the public from the American Heart Association Emergency Cardiovascular Care Committee. Circulation 2008; 117:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/39\">",
"      Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/40\">",
"      Thompson RG, Hallstrom AP, Cobb LA. Bystander-initiated cardiopulmonary resuscitation in the management of ventricular fibrillation. Ann Intern Med 1979; 90:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/41\">",
"      Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med 2004; 351:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/42\">",
"      Valenzuela TD, Roe DJ, Cretin S, et al. Estimating effectiveness of cardiac arrest interventions: a logistic regression survival model. Circulation 1997; 96:3308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/43\">",
"      Adielsson A, Hollenberg J, Karlsson T, et al. Increase in survival and bystander CPR in out-of-hospital shockable arrhythmia: bystander CPR and female gender are predictors of improved outcome. Experiences from Sweden in an 18-year perspective. Heart 2011; 97:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/44\">",
"      Sasson C, Magid DJ, Chan P, et al. Association of neighborhood characteristics with bystander-initiated CPR. N Engl J Med 2012; 367:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/45\">",
"      Bobrow BJ, Spaite DW, Berg RA, et al. Chest compression-only CPR by lay rescuers and survival from out-of-hospital cardiac arrest. JAMA 2010; 304:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/46\">",
"      SOS-KANTO study group. Cardiopulmonary resuscitation by bystanders with chest compression only (SOS-KANTO): an observational study. Lancet 2007; 369:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/47\">",
"      Iwami T, Kawamura T, Hiraide A, et al. Effectiveness of bystander-initiated cardiac-only resuscitation for patients with out-of-hospital cardiac arrest. Circulation 2007; 116:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/48\">",
"      Bohm K, Rosenqvist M, Herlitz J, et al. Survival is similar after standard treatment and chest compression only in out-of-hospital bystander cardiopulmonary resuscitation. Circulation 2007; 116:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/49\">",
"      Rea TD, Fahrenbruch C, Culley L, et al. CPR with chest compression alone or with rescue breathing. N Engl J Med 2010; 363:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/50\">",
"      Svensson L, Bohm K, Castr&egrave;n M, et al. Compression-only CPR or standard CPR in out-of-hospital cardiac arrest. N Engl J Med 2010; 363:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/51\">",
"      Hallstrom A, Cobb L, Johnson E, Copass M. Cardiopulmonary resuscitation by chest compression alone or with mouth-to-mouth ventilation. N Engl J Med 2000; 342:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/52\">",
"      H&uuml;pfl M, Selig HF, Nagele P. Chest-compression-only versus standard cardiopulmonary resuscitation: a meta-analysis. Lancet 2010; 376:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/53\">",
"      Dumas F, Rea TD, Fahrenbruch C, et al. Chest compression alone cardiopulmonary resuscitation is associated with better long-term survival compared with standard cardiopulmonary resuscitation. Circulation 2013; 127:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/54\">",
"      Berdowski J, ten Haaf M, Tijssen JG, et al. Time in recurrent ventricular fibrillation and survival after out-of-hospital cardiac arrest. Circulation 2010; 122:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/55\">",
"      Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA 1999; 281:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/56\">",
"      Wik L, Hansen TB, Fylling F, et al. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial. JAMA 2003; 289:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/57\">",
"      Stiell IG, Nichol G, Leroux BG, et al. Early versus later rhythm analysis in patients with out-of-hospital cardiac arrest. N Engl J Med 2011; 365:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/58\">",
"      Verbeek PR, Vermeulen MJ, Ali FH, et al. Derivation of a termination-of-resuscitation guideline for emergency medical technicians using automated external defibrillators. Acad Emerg Med 2002; 9:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/59\">",
"      Morrison LJ, Verbeek PR, Vermeulen MJ, et al. Derivation and evaluation of a termination of resuscitation clinical prediction rule for advanced life support providers. Resuscitation 2007; 74:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/60\">",
"      Sasson C, Hegg AJ, Macy M, et al. Prehospital termination of resuscitation in cases of refractory out-of-hospital cardiac arrest. JAMA 2008; 300:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/61\">",
"      Idris AH, Guffey D, Aufderheide TP, et al. Relationship between chest compression rates and outcomes from cardiac arrest. Circulation 2012; 125:3004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/62\">",
"      Zeiner A, Holzer M, Sterz F, et al. Hyperthermia after cardiac arrest is associated with an unfavorable neurologic outcome. Arch Intern Med 2001; 161:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/63\">",
"      Woodall J, McCarthy M, Johnston T, et al. Impact of advanced cardiac life support-skilled paramedics on survival from out-of-hospital cardiac arrest in a statewide emergency medical service. Emerg Med J 2007; 24:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/64\">",
"      Tresch DD, Thakur RK, Hoffmann RG, et al. Comparison of outcome of paramedic-witnessed cardiac arrest in patients younger and older than 70 years. Am J Cardiol 1990; 65:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/65\">",
"      Longstreth WT Jr, Cobb LA, Fahrenbruch CE, Copass MK. Does age affect outcomes of out-of-hospital cardiopulmonary resuscitation? JAMA 1990; 264:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/66\">",
"      Wuerz RC, Holliman CJ, Meador SA, et al. Effect of age on prehospital cardiac resuscitation outcome. Am J Emerg Med 1995; 13:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/67\">",
"      Van Hoeyweghen RJ, Bossaert LL, Mullie A, et al. Survival after out-of-hospital cardiac arrest in elderly patients. Belgian Cerebral Resuscitation Study Group. Ann Emerg Med 1992; 21:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/68\">",
"      Kim C, Becker L, Eisenberg MS. Out-of-hospital cardiac arrest in octogenarians and nonagenarians. Arch Intern Med 2000; 160:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/69\">",
"      Akahane M, Ogawa T, Koike S, et al. The effects of sex on out-of-hospital cardiac arrest outcomes. Am J Med 2011; 124:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/70\">",
"      Kim C, Fahrenbruch CE, Cobb LA, Eisenberg MS. Out-of-hospital cardiac arrest in men and women. Circulation 2001; 104:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/71\">",
"      Carew HT, Zhang W, Rea TD. Chronic health conditions and survival after out-of-hospital ventricular fibrillation cardiac arrest. Heart 2007; 93:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/72\">",
"      van Walraven C, Forster AJ, Parish DC, et al. Validation of a clinical decision aid to discontinue in-hospital cardiac arrest resuscitations. JAMA 2001; 285:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/73\">",
"      Brindley PG, Markland DM, Mayers I, Kutsogiannis DJ. Predictors of survival following in-hospital adult cardiopulmonary resuscitation. CMAJ 2002; 167:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/74\">",
"      Bloom HL, Shukrullah I, Cuellar JR, et al. Long-term survival after successful inhospital cardiac arrest resuscitation. Am Heart J 2007; 153:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/75\">",
"      Goldberger ZD, Chan PS, Berg RA, et al. Duration of resuscitation efforts and survival after in-hospital cardiac arrest: an observational study. Lancet 2012; 380:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/76\">",
"      Chan PS, Krumholz HM, Nichol G, et al. Delayed time to defibrillation after in-hospital cardiac arrest. N Engl J Med 2008; 358:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/77\">",
"      Chan PS, Krumholz HM, Spertus JA, et al. Automated external defibrillators and survival after in-hospital cardiac arrest. JAMA 2010; 304:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/78\">",
"      Neumar RW, Nolan JP, Adrie C, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council. Circulation 2008; 118:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/79\">",
"      Kilgannon JH, Jones AE, Shapiro NI, et al. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. JAMA 2010; 303:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30041/abstract/80\">",
"      Bunch TJ, White RD, Gersh BJ, et al. Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med 2003; 348:2626.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 973 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-0039180376-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30041=[""].join("\n");
var outline_f29_21_30041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30436139\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS FOLLOWING SUDDEN CARDIAC ARREST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OUTCOME ACCORDING TO ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Asystole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pulseless electrical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ventricular tachyarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H594215622\">",
"      SCA due to noncardiac causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FACTORS AFFECTING OUT-OF-HOSPITAL SCA OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      VF duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Time to resuscitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bystander CPR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H93796253\">",
"      Chest compression-only CPR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Timing of defibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Automated external defibrillators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Predictive value of BLS and ALS rules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adequacy of CPR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Body temperature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prehospital ACLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Effect of older age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Effect of gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Effect of comorbidities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FACTORS AFFECTING IN-HOSPITAL SCA OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      IMPACT OF ARTERIAL OXYGEN LEVEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LONG-TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30436139\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/973|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/63/44022\" title=\"algorithm 1\">",
"      Adult cardiac arrest algorithm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=related_link\">",
"      Automated external defibrillators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=related_link\">",
"      Post-cardiac arrest management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_21_30042="Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children";
var content_f29_21_30042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/21/30042/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30042/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/21/30042/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30042/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/21/30042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/21/30042/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/21/30042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shortly after the introduction of methicillin in 1959, outbreaks of methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    (MRSA) infections were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology and clinical spectrum of MRSA infections in children will be reviewed here. The treatment and prevention of MRSA infections in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26792?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, treatment, and prevention of MRSA infections in adults are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MRSA DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin resistance in",
"    <em>",
"     S. aureus",
"    </em>",
"    is defined as an",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    minimum inhibitory concentration (MIC) &ge;4",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Isolates resistant to oxacillin or methicillin also are resistant to all beta-lactam agents, including cephalosporins (with the exception of ceftobiprole and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Methicillin resistance is mediated by the mecA gene, which encodes for an abnormal low-affinity binding protein, PBP-2a, that permits the organism to grow and divide in the presence of methicillin and other beta-lactam antibiotics. The mecA gene is located on a mobile genetic element called staphylococcal cassette chromosome (SCCmec). A single clone probably accounted for most methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) isolates recovered during the 1960s; by 2002, five major MRSA clones emerged worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Dissemination of resistance was mediated by horizontal transfer of the mecA gene and related regulatory sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) has traditionally been classified into health-care-associated (HA-MRSA) and community-associated (CA-MRSA). However, the HA-MRSA and CA-MRSA classifications are no longer distinct [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. HA-MRSA can spread to community contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/7,11\">",
"     7,11",
"    </a>",
"    ], and CA-MRSA is becoming a significant cause of health-care-associated infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/9,12-17\">",
"     9,12-17",
"    </a>",
"    ]. Thus, some authorities, including the US Centers for Disease Control and Prevention Active Bacterial Core (CDC ABC) Surveillance System, subdivide HA-MRSA according to the setting of onset (hospital or community) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/12,16,18\">",
"     12,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several criteria are used to classify MRSA infections into one of these groups, although the classification scheme has not been standardized [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The criteria include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The time of isolation (eg, an infection is considered to have onset in the hospital if the pathogen is isolated after a certain time period (variably defined, but usually 48 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/12,19,21\">",
"       12,19,21",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Host risk factor profile (although the risk factors are not standardized)",
"     </li>",
"     <li>",
"      Antimicrobial susceptibility pattern (with CA-MRSA usually resistant to two or fewer classes of antibiotics, and HA-MRSA resistant to three or more)",
"     </li>",
"     <li>",
"      Molecular characteristics of the isolate, including the SCCmec type, pulsed-field gel electrophoresis (PFGE) type, and presence of the genes for Panton-Valentine leukocidin (PVL) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Microbiologic characteristics'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     HA-MRSA infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health-care-associated MRSA is usually defined by MRSA infection in a patient with one of the following risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/12,22\">",
"     12,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of an invasive device at the time of onset of infection",
"     </li>",
"     <li>",
"      History of HA-MRSA infection or colonization",
"     </li>",
"     <li>",
"      History of surgery, hospitalization, dialysis, or residence in a long-term care facility in the 12 months preceding culture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A previous history of CA-MRSA infection is not, by itself, a risk factor for HA-MRSA infection. However, if treatment of the CA-MRSA infection required hospitalization, the patient would be at risk for HA-MRSA as described in the third bullet above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hospital-onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC ABC Surveillance System defines invasive hospital-onset (nosocomial) HA-MRSA as cases with positive culture result from normally sterile site obtained &gt;48 hours after hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/12\">",
"     12",
"    </a>",
"    ]. These cases might have one or more of the risk factors for HA-MRSA, described above (see",
"    <a class=\"local\" href=\"#H4\">",
"     'HA-MRSA infections'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Community-onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC ABC Surveillance System defines invasive community-onset HA-MRSA (CO HA-MRSA, also called nonnosocomial health-care-associated MRSA) as cases with onset in the community and at least one of the health-care risk factors described above (see",
"    <a class=\"local\" href=\"#H4\">",
"     'HA-MRSA infections'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/12\">",
"     12",
"    </a>",
"    ]. Underlying illness possibly predisposing to frequent hospitalizations or visits to medical facilities is another risk factor for CO HA-MRSA infection in children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/15,16,18\">",
"     15,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the defining risk factors for CO HA-MRSA are similar to those for nosocomial infection, the molecular characteristics of MRSA isolated from children in this group more closely resemble those of CA-MRSA strains [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Microbiologic characteristics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CA-MRSA infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-associated MRSA (CA-MRSA) usually is defined as an MRSA infection with onset in the community in a patient who is without risk factors for HA-MRSA, although the defining risk factors have varied from study to study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term CA-MRSA also has been used to refer to MRSA strains with bacteriologic characteristics (eg, genotype, antimicrobial susceptibility patterns) typical of isolates obtained from patients with CA-MRSA infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'CA-MRSA strains'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MICROBIOLOGIC CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several microbiologic features, including antimicrobial susceptibility patterns, PFGE type, SCCmec type, and presence or absence of PVL, have traditionally distinguished health-care-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (HA-MRSA) strains from community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA) strains [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, as CA-MRSA isolates move into the hospital, it has become more difficult, using molecular techniques, to determine whether methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) isolates associated with an outbreak are related to health-care workers, other patients, the hospital environment, or the community [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/9,12-17\">",
"     9,12-17",
"    </a>",
"    ]. Rapid whole-genome sequencing may be helpful in this regard, but is not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observation that CA-MRSA and HA-MRSA strains initially were genetically distinct suggests that CA-MRSA strains did not originate from spread of nosocomial strains into the community [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/25,28,29\">",
"     25,28,29",
"    </a>",
"    ]. However, CA-MRSA appears to be related to some clones of community methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    (MSSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/23\">",
"     23",
"    </a>",
"    ]. Strains of MSSA with PVL genes and PFGE patterns closely related to MRSA USA300 and USA400 have been isolated from patients with community-associated MSSA infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Between 2001 and 2006, approximately 25 percent of invasive CA-MSSA isolates at a single children's hospital were USA300; the proportion of USA300 increased from 14 percent to 35 percent during the study period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/33\">",
"     33",
"    </a>",
"    ]. Strains of MSSA with Panton-Valentine leukocidin (PVL) genes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulsed-field gel electrophoresis (PFGE) patterns closely related to MRSA USA300 and USA400 may represent ancestors of the MRSA strains or MRSA strains that have lost mecA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     HA-MRSA strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;HA-MRSA strains tend to have multidrug resistance and carry staphylococcal cassette chromosome type II (SCCmec type II) or SCCmec type III [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/25,34\">",
"     25,34",
"    </a>",
"    ]. HA-MRSA strains are typified by a USA100 or USA200 PFGE pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/35\">",
"     35",
"    </a>",
"    ]. SCCmec type IV, which is most typical of CA-MRSA strains, is also found in some HA-MRSA PFGE types [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     CA-MRSA strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most CA-MRSA strains are susceptible to nonbeta-lactam antibiotics. However, resistance to commonly prescribed antibiotics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , fluoroquinolones, tetracyclines,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=see_link\">",
"     mupirocin",
"    </a>",
"    ) appears to be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/16,36-38\">",
"     16,36-38",
"    </a>",
"    ]. Local antimicrobial susceptibility patterns influence treatment of suspected or confirmed",
"    <em>",
"     S. aureus",
"    </em>",
"    infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Approach for children &gt;30 days of age'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most CA-MRSA strains carry staphylococcal cassette chromosome (SCCmec) type IV or V [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/10,28\">",
"     10,28",
"    </a>",
"    ]. These types are smaller and theoretically more easily transferable between organisms than SCCmec types I-III [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/23,39\">",
"     23,39",
"    </a>",
"    ]. CA-MRSA strains are typified by a USA300 or USA400 PFGE pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/35,40,41\">",
"     35,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CA-MRSA strains frequently carry genes for PVL, a cytotoxin that confers enhanced virulence in both MSSA and MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/33,42-45\">",
"     33,42-45",
"    </a>",
"    ]. The presence of PVL is associated with increased morbidity in children with osteomyelitis and increased mortality in patients with",
"    <em>",
"     S. aureus",
"    </em>",
"    pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. PVL and other virulence determinants for MRSA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40758?source=see_link&amp;anchor=H3#H3\">",
"     \"Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus\", section on 'Virulence determinants and their regulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CA-MRSA strains also produce high concentrations of peptides that recruit, activate, and lyse neutrophils, which are the main component of the host's cellular defense against",
"    <em>",
"     S. aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/50\">",
"     50",
"    </a>",
"    ]. These cytolytic peptides may account, at least in part, for the increased virulence of CA-MRSA compared with nosocomial MRSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     CO HA-MRSA strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRSA strains isolated from children with risk factors for HA-MRSA and onset of infection in the community share features of HA-MRSA and CA-MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Most CO HA-MRSA strains carry the SCCmec type IV cassette, suggesting that CA-MRSA strains are now endemic in hospital settings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case series, CO HA-MRSA had greater PFGE molecular diversity, were less likely to contain sequences for PVL, and more likely to be resistant to &ge;3 classes of antibiotics than CA-MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/15\">",
"     15",
"    </a>",
"    ]. This observation has important implications when choosing empiric therapy for suspected MRSA infection and highlights the importance of differentiating between CO-HA-MRSA and CA-MRSA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Approach for children &gt;30 days of age'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1183236\">",
"    <span class=\"h2\">",
"     Linezolid resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    resistance has been observed among methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates. The mechanism appears to be via the bacterial cfr gene, which resides in a potentially mobile genetic element [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Linezolid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) was initially a nosocomial pathogen, with only small numbers of community-acquired cases, but has become an increasingly prevalent community-acquired pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/18,52,53\">",
"     18,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nosocomial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of health-care-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (HA-MRSA) among hospitalized patients varies geographically. It is generally high in the United States, Japan, and southern Europe (eg, &gt;30 percent in Spain, France, and Italy) but is very low (&lt;1 percent) in Scandinavia and Switzerland [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/54-60\">",
"     54-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRSA isolates account for approximately 60 percent of",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates from hospitalized patients in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/38,60,61\">",
"     38,60,61",
"    </a>",
"    ]. The proportion of",
"    <em>",
"     S. aureus",
"    </em>",
"    bloodstream infections caused by MRSA increased from 27 percent during 1990-1994 to 54 percent during 2000-2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/62\">",
"     62",
"    </a>",
"    ]. However, invasive nosocomial MRSA infections are relatively rare in children older than one year of age. During 14 years of surveillance (1990-2003) from a single children's hospital, the annual number of cases of nosocomial MRSA ranged between one and eight throughout the study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/18\">",
"     18",
"    </a>",
"    ]. In 2003, only 2 percent of 467 MRSA cases were nosocomial.",
"   </p>",
"   <p>",
"    Invasive nosocomial infections predominantly occur in children younger than one year of age (incidence of 14.7 per 100,000 versus &le;1 per 100,000 in older children) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/12\">",
"     12",
"    </a>",
"    ]. The data were not analyzed to determine if this group consists predominantly of infants in the neonatal intensive care unit (NICU). However, the increased rate of invasive CA-MRSA infections in children younger than one year of age suggests that the risk of invasive nosocomial infection in children younger than one year of age is not limited to children in the NICU.",
"   </p>",
"   <p>",
"    Risk factors for nosocomial MRSA infection are listed below; the first three are the risk factors that traditionally define HA-MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of an invasive device at the time of admission",
"     </li>",
"     <li>",
"      History of MRSA infection or colonization [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/63\">",
"       63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      History of surgery, hospitalization, dialysis, or residence in a long-term care facility in the 12 months preceding culture",
"     </li>",
"     <li>",
"      Prolonged hospitalization (&gt;14 days)",
"     </li>",
"     <li>",
"      Surgery or surgical site infection",
"     </li>",
"     <li>",
"      Admission to intensive care unit or burn unit",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Endotracheal/tracheostomy/nasogastric",
"      </span>",
"      tube",
"     </li>",
"     <li>",
"      Parenteral",
"      <span class=\"nowrap\">",
"       nutrition/enteral",
"      </span>",
"      feedings",
"     </li>",
"     <li>",
"      Proximity to others with MRSA colonization or infection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/64\">",
"       64",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     CA-MRSA infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of CA-MRSA varies geographically [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/10,22\">",
"     10,22",
"    </a>",
"    ]. However, surveillance from individual health-care facilities has demonstrated an increasing prevalence of CA-MRSA infections, increasing proportions of community-associated",
"    <em>",
"     S. aureus",
"    </em>",
"    infections that are MRSA, and increasing proportions of MRSA that are CA-MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/10,18,26,28,65,66\">",
"     10,18,26,28,65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the Pediatric Health Information System, which includes &gt;40 freestanding children's hospitals in the United States, indicates that for the period between 2002 through 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRSA accounted for 51 percent of",
"      <em>",
"       S. aureus",
"      </em>",
"      hospitalizations in 57,974 children",
"     </li>",
"     <li>",
"      The incidence of MRSA infection increased from 6.7 to 21.1 cases per 1000 admissions between 2002 and 2007; the incidence of MSSA remained stable (14.1 to 14.7 cases per 1000 patient days)",
"     </li>",
"     <li>",
"      Skin and soft tissue infections (SSTI) accounted for 61 percent of",
"      <em>",
"       S. aureus",
"      </em>",
"      infections that were characterized by site of infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Community outbreaks of skin and soft tissue infection (SSTI) have been reported in multiple settings, including native and aboriginal communities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/41,67\">",
"     41,67",
"    </a>",
"    ], sports teams [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/68-71\">",
"     68-71",
"    </a>",
"    ], child-care centers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/11,72\">",
"     11,72",
"    </a>",
"    ], military personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], men who have sex with men [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/75\">",
"     75",
"    </a>",
"    ], and prison inmates and guards [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/71,74,76,77\">",
"     71,74,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of CA-MRSA outbreaks indicates several risk factors that have a relatively poor predictive value for CA-MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin trauma (eg, \"turf burns,\" lacerations or abrasions, cosmetic body shaving, body piercing, tattoo placement) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/69,78,79\">",
"       69,78,79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Crowding",
"     </li>",
"     <li>",
"      Frequent skin-to-skin contact [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sharing potentially contaminated personal items or equipment that is not cleaned or laundered between users (eg, razors, sports equipment, towels) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Challenges in maintaining personal cleanliness and hygiene",
"     </li>",
"     <li>",
"      Limited access to health care [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/80\">",
"       80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Frequent exposure to antimicrobial agents [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in most areas of the United States, CA-MRSA should be considered in any child presenting in the community with an infection for which",
"    <em>",
"     S. aureus",
"    </em>",
"    is a potential etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     CO HA-MRSA infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for CO HA-MRSA are not standardized; those identified in publications describing this category [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/15,16,18\">",
"     15,16,18",
"    </a>",
"    ] or review articles [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/20\">",
"     20",
"    </a>",
"    ] are listed below; the first three traditionally define HA-MRSA:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of an invasive device",
"     </li>",
"     <li>",
"      History of HA-MRSA infection or colonization",
"     </li>",
"     <li>",
"      History of surgery, hospitalization, dialysis, or residence in a long-term care facility in the 12 months preceding culture",
"     </li>",
"     <li>",
"      Chronic disease (other than asthma or eczema)",
"     </li>",
"     <li>",
"      Antibiotic use in the previous six months",
"     </li>",
"     <li>",
"      Tympanostomy tube for recurrent otitis media",
"     </li>",
"     <li>",
"      Day-care center attendance",
"     </li>",
"     <li>",
"      Household contact with identified risk factor",
"     </li>",
"     <li>",
"      Age younger than two years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) transmission requires contact with a colonized individual or a contaminated surface. Adherence to infection control measures is critical for interrupting MRSA transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26792?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in children\", section on 'Prevention of transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three major reservoirs of MRSA are patients, health-care workers, and perhaps the inanimate environment. Patients are the greatest source of transmission in the health-care setting. Term and late-preterm infants may acquire infection from their mothers, some other source in the community, or possibly the nursery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/17,53,83-85\">",
"     17,53,83-85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Colonized individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals colonized with MRSA serve as a reservoir for transmission. MRSA can colonize the skin and nares of hospitalized patients, health-care workers, and healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/63,86-88\">",
"     63,86-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colonization with",
"    <em>",
"     S. aureus",
"    </em>",
"    is a risk factor for subsequent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/63,89-91\">",
"     63,89-91",
"    </a>",
"    ]. In a review of 758 hospitalized patients, MRSA colonization was observed in 3.4 percent of admissions and acquired in an additional 3 percent; the rates of MRSA infection within one year in these groups were 19 and 25 percent (relative risks 9.5 and 13 compared with patients with no colonization or methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    [MSSA] colonization, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colonization can occur in the following ways [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Contact with contaminated wounds or dressings of infected patients",
"     </li>",
"     <li>",
"      Contact with another individual's colonized intact skin",
"     </li>",
"     <li>",
"      Contact with contaminated inanimate objects (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Contaminated surfaces'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Inhalation of aerosolized droplets from chronic nasal carriers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals with nasal MRSA carriage transmit MRSA more readily in the setting of concomitant sinus infection or upper respiratory infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Health-care workers with dermatitis that is infected or colonized with MRSA are particularly prone to transmitting the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/96,97\">",
"     96,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anterior nares is the most common site of MRSA colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/92,98\">",
"     92,98",
"    </a>",
"    ]. The durability of MRSA colonization can vary from a few days or weeks to up to several years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/93,98\">",
"     93,98",
"    </a>",
"    ]. In one report of patients requiring readmission to a hospital, the median length of colonization was 40 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to 30 percent of individuals with nasal colonization are also colonized on other areas of intact skin including the hands, axillae, perineum, and umbilicus (in infants) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/92,99-103\">",
"     92,99-103",
"    </a>",
"    ]. Other potential sites of MRSA colonization include surgical wounds, decubitus ulcers, intravascular catheter sites, throat, sputum, stool, and genitourinary tract. The throat was the second most colonized site (after the nose) in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surveillance during the National Health and Nutrition Survey indicates that the overall prevalence of nasal colonization among children (age 1 to 19 years) in the United States during 2003-2004 was 1.3 percent (increased from 0.6 percent in 2001-2002) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/105\">",
"     105",
"    </a>",
"    ]. Colonization rates were increased in children &gt;5 years compared with those aged one to five years.",
"   </p>",
"   <p>",
"    The prevalence of nasal colonization with MRSA varies depending upon the population, with rates of approximately 10 percent among healthy children in the United States attending health maintenance visits in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/106\">",
"     106",
"    </a>",
"    ], 22 percent among children admitted to a single children's hospital in the United States in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/107\">",
"     107",
"    </a>",
"    ], and &lt;1 percent among hospitalized children in Switzerland and healthy schoolchildren in Germany [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/56,108\">",
"     56,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a given region, colonization rates may vary from practice to practice. Multipractice surveillance among children presenting for health-maintenance or acute-care visits in a single metropolitan area of the United States during 2005-2006 demonstrated colonization rates ranging from 0 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nasal colonization in children appears to be increased in children who have been immunized with the conjugate pneumococcal vaccine, probably due to competition between vaccine-type pneumococci and",
"    <em>",
"     S. aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. It also may be related to exposure to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    in the preceding three months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=see_link&amp;anchor=H8#H8\">",
"     \"Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States\", section on 'Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Contaminated surfaces",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRSA-contaminated surfaces also can serve as reservoirs for MRSA transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]. Health-care workers who touch contaminated surfaces may contaminate their gloves (or presumably their hands) with MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/112\">",
"     112",
"    </a>",
"    ]. The extent to which contaminated environmental surfaces contribute to transmission of MRSA to patients has not been established.",
"   </p>",
"   <p>",
"    The risk of contamination of inanimate surfaces in patient rooms may depend upon the patient's site of MRSA infection. In a prospective culture survey of a 200-bed hospital, cultures obtained from inanimate surfaces in the hospital rooms of MRSA-infected patients were positive more frequently in the setting of wound infections or urinary tract infections than in the setting of MRSA infection at other sites (36 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRSA also may be transmissible through contact with medical equipment (eg, tourniquets, stethoscopes, blood pressure cuffs) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/112-115\">",
"     112-115",
"    </a>",
"    ]. In a study of cultures from 200 stethoscope ear tips, 80 percent were contaminated with microorganisms. Among the positive cultures, 58 percent were Staphylococcus species, and 17 percent were MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contaminated surfaces that may play a role in the transmission of MRSA in the community include surfaces to which people have bare skin contact [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/23,81,116\">",
"     23,81,116",
"    </a>",
"    ]. These include towels, razors, sauna benches, sports equipment, and exercise mats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CLINICAL SPECTRUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) infection ranges from asymptomatic colonization, to skin and soft tissue infection (SSTI), to life-threatening invasive infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/23\">",
"     23",
"    </a>",
"    ]. Colonization is discussed above. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Colonized individuals'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nosocomial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 30 and 60 percent of hospitalized patients who are colonized with MRSA develop an overt infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nosocomial MRSA is associated with severe, invasive disease in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/12,15,18,60,118,119\">",
"     12,15,18,60,118,119",
"    </a>",
"    ]. MRSA is one of the few pathogens routinely implicated in nearly every type of nosocomial infection. This is probably related to its capacity for biofilm formation on nosocomial foreign devices (eg, endotracheal tubes, urinary catheters, intravascular catheters).",
"   </p>",
"   <p>",
"    The body sites most frequently affected by nosocomial MRSA are wounds, skin, and bloodstream, followed by the lower respiratory tract and urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/12,18,22,65\">",
"     12,18,22,65",
"    </a>",
"    ]. During 14 years of surveillance at a single children's hospital, 74 children developed nosocomial MRSA infection, of which 66 percent were invasive (primarily of the lungs and bloodstream) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with MRSA infection have higher mortality, longer hospital stays, and higher health-care costs than patients with methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    (MSSA) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/119-124\">",
"     119-124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Community infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA) isolates are most often associated with SSTI. However, CA-MRSA is increasingly noted as a cause of invasive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     SSTI",
"    </span>",
"    &nbsp;&mdash;&nbsp;CA-MRSA isolates are most often associated with SSTI, which have accounted for up to 96 percent of cases of CA-MRSA infection in various series limited to children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/18,53,65,125\">",
"     18,53,65,125",
"    </a>",
"    ]. The predilection of CA-MRSA strains to cause SSTI may be related at least in part to the presence of Panton-Valentine leukocidin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CA-MRSA strains have been cultured from pustules, furuncles (abscessed hair follicles or \"boils\"), carbuncles (coalesced masses of furuncles), and skin abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/23\">",
"     23",
"    </a>",
"    ]. The role of MRSA in cellulitis is less clear since cultures are rarely obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/23\">",
"     23",
"    </a>",
"    ]. Staphylococcal SSTI may be confused with spider bites by both patients and clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/23\">",
"     23",
"    </a>",
"    ]. The evaluation and management of MRSA SSTI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Invasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;CA-MRSA is increasingly noted as a cause of invasive disease, although less frequently than of SSTI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/12,46,127-132\">",
"     12,46,127-132",
"    </a>",
"    ]. Invasive disease may occur as a complication of SSTI or spontaneously in patients without previous infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/23,132\">",
"     23,132",
"    </a>",
"    ]. Disseminated disease may occur as a consequence of bacteremia.",
"   </p>",
"   <p>",
"    Invasive disease occurs more often in children with risk factors for HA-MRSA than in children without such risk factors (32 versus 5 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. Acute hematogenous osteomyelitis is the most common invasive disease caused by CA-MRSA in children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/46,133\">",
"     46,133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17416?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children\", section on 'Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other types of invasive MRSA disease reported in children include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bacteremia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/128\">",
"       128",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pneumonia (often necrotizing) and empyema, sometimes as a fatal complication of influenza [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/127,130-132,134,135\">",
"       127,130-132,134,135",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=see_link&amp;anchor=H16#H16\">",
"       \"Epidemiology, pathogenesis, and etiology of pneumonia in children\", section on 'Overview'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pyomyositis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/30,46,136-138\">",
"       30,46,136-138",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sinusitis",
"     </li>",
"     <li>",
"      Retropharyngeal abscess [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/139\">",
"       139",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lymphadenitis",
"     </li>",
"     <li>",
"      Orbital cellulitis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/140\">",
"       140",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Endocarditis",
"     </li>",
"     <li>",
"      Sepsis (with or without Waterhouse-Friderichsen syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other sites of infection include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Otitis media [",
"      <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/141\">",
"       141",
"      </a>",
"      ] and otitis externa",
"     </li>",
"     <li>",
"      Sinusitis (which may be invasive if it is associated with complications)",
"     </li>",
"     <li>",
"      Urinary tract infection (which is invasive if it affects the upper urinary tract (ie, pyelonephritis))",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with community-associated MSSA invasive disease, CA-MRSA invasive disease is associated with increased severity, complications, and risk of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/30,133,142\">",
"     30,133,142",
"    </a>",
"    ]. This was illustrated in a series of 158 cases of acute osteoarticular infection from a single institution in which MRSA infections were associated with increased rate of subperiosteal abscess formation (71 versus 38 percent), increased need for surgical drainage (91 versus 62 percent) and increased median hospital stay (10 versus 7 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of invasive MRSA infections in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     In young infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of community-associated",
"    <em>",
"     S. aureus",
"    </em>",
"    infections in term and late-preterm previously healthy infants younger than 30 days of age was described in a series of 126 infants from a single institution [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/125\">",
"     125",
"    </a>",
"    ]. Two-thirds of isolates were MRSA. There were 43 cases of pustulosis, 68 of",
"    <span class=\"nowrap\">",
"     cellulitis/abscess,",
"    </span>",
"    and 15 invasive infections. As in older children, the morbidity of CA-MRSA compared with CA-MSSA infections in neonates appears to be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?29/21/30042/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Methicillin-resistant",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      (MRSA) has traditionally been classified into health-care associated (HA-MRSA) and community-associated (CA-MRSA). However, these classifications are becoming less distinct. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HA-MRSA strains tend to have multidrug resistance and carry staphylococcal cassette chromosome type II (SCCmec type II) or SCCmec type III. HA-MRSA strains are typified by a USA100 or USA200 pulse-field gel electrophoresis (PFGE) pattern. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'HA-MRSA strains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CA-MRSA strains are usually susceptible to nonbeta-lactam antibiotics, although local susceptibility patterns vary. CA-MRSA strains typically carry staphylococcal cassette chromosome type IV or V and have a USA300 or USA400 PFGE pattern. They also frequently carry genes for Panton-Valentine leukocidin. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'CA-MRSA strains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MRSA strains isolated from children with risk factors for HA-MRSA and onset of infection in the community (CO HA-MRSA) share features of HA-MRSA and CA-MRSA. Similar to CA-MRSA, most CO HA-MRSA strains carry the SCCmec type IV cassette. However, they have greater diversity in PFGE patterns, are less likely to contain sequences for PVL, and are more likely to be resistant to &ge;3 classes of antibiotics than CA-MRSA. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'CO HA-MRSA strains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for CA-MRSA include skin trauma, crowding, frequent skin-to-skin contact, sharing potentially contaminated personal items or equipment, and frequent exposure to antimicrobial agents. However, they have a relatively poor ability to distinguish MRSA from methicillin-sensitive",
"      <em>",
"       S. aureus",
"      </em>",
"      infection, and CA-MRSA should be considered in any child presenting in the community with an infection for which",
"      <em>",
"       S. aureus",
"      </em>",
"      is a potential etiology. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MRSA transmission requires contact with a colonized individual or a contaminated surface. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical spectrum of MRSA infection ranges from asymptomatic colonization, to skin and soft tissue infection, to life-threatening invasive infection. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Clinical spectrum'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/1\">",
"      Benner EJ, Kayser FH. Growing clinical significance of methcillin-resistant Staphylococcus aureus. Lancet 1968; 2:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/2\">",
"      Kreiswirth B, Kornblum J, Arbeit RD, et al. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science 1993; 259:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/3\">",
"      Cris&oacute;stomo MI, Westh H, Tomasz A, et al. The evolution of methicillin resistance in Staphylococcus aureus: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones. Proc Natl Acad Sci U S A 2001; 98:9865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/4\">",
"      Enright MC, Robinson DA, Randle G, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A 2002; 99:7687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/5\">",
"      Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/6\">",
"      Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/7\">",
"      Calfee DP, Durbin LJ, Germanson TP, et al. Spread of methicillin-resistant Staphylococcus aureus (MRSA) among household contacts of individuals with nosocomially acquired MRSA. Infect Control Hosp Epidemiol 2003; 24:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/8\">",
"      Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/9\">",
"      Maree CL, Daum RS, Boyle-Vavra S, et al. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis 2007; 13:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/10\">",
"      Adedeji A, Weller TM, Gray JW. MRSA in children presenting to hospitals in Birmingham, UK. J Hosp Infect 2007; 65:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/11\">",
"      Adcock PM, Pastor P, Medley F, et al. Methicillin-resistant Staphylococcus aureus in two child care centers. J Infect Dis 1998; 178:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/12\">",
"      Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/13\">",
"      Healy CM, Hulten KG, Palazzi DL, et al. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin Infect Dis 2004; 39:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/14\">",
"      Saiman L, O'Keefe M, Graham PL 3rd, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003; 37:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/15\">",
"      Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003. Pediatr Infect Dis J 2006; 25:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/16\">",
"      Hult&eacute;n KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children. Pediatr Infect Dis J 2006; 25:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns--Chicago and Los Angeles County, 2004. MMWR Morb Mortal Wkly Rep 2006; 55:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/18\">",
"      Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005; 159:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/19\">",
"      David MZ, Crawford SE, Boyle-Vavra S, et al. Contrasting pediatric and adult methicillin-resistant Staphylococcus aureus isolates. Emerg Infect Dis 2006; 12:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/20\">",
"      Paintsil E. Pediatric community-acquired methicillin-resistant Staphylococcus aureus infection and colonization: trends and management. Curr Opin Pediatr 2007; 19:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/21\">",
"      Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/22\">",
"      Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/23\">",
"      Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2008; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/24\">",
"      Bratu S, Eramo A, Kopec R, et al. Community-associated methicillin-resistant Staphylococcus aureus in hospital nursery and maternity units. Emerg Infect Dis 2005; 11:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/25\">",
"      Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/26\">",
"      Mishaan AM, Mason EO Jr, Martinez-Aguilar G, et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr Infect Dis J 2005; 24:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/27\">",
"      K&ouml;ser CU, Holden MT, Ellington MJ, et al. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N Engl J Med 2012; 366:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/28\">",
"      Buckingham SC, McDougal LK, Cathey LD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee Children's Hospital. Pediatr Infect Dis J 2004; 23:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/29\">",
"      Salmenlinna S, Lyytik&auml;inen O, Vuopio-Varkila J. Community-acquired methicillin-resistant Staphylococcus aureus, Finland. Emerg Infect Dis 2002; 8:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/30\">",
"      Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe Staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005; 115:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/31\">",
"      Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/32\">",
"      Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/33\">",
"      McCaskill ML, Mason EO Jr, Kaplan SL, et al. Increase of the USA300 clone among community-acquired methicillin-susceptible Staphylococcus aureus causing invasive infections. Pediatr Infect Dis J 2007; 26:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/34\">",
"      Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/35\">",
"      McDougal LK, Steward CD, Killgore GE, et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003; 41:5113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/36\">",
"      Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007; 45:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/37\">",
"      Braun L, Craft D, Williams R, et al. Increasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilities. Pediatr Infect Dis J 2005; 24:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/38\">",
"      Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/39\">",
"      Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 2007; 87:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/40\">",
"      Saravolatz LD, Markowitz N, Arking L, et al. Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. Ann Intern Med 1982; 96:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/41\">",
"      Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001; 286:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/42\">",
"      Baba T, Takeuchi F, Kuroda M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/43\">",
"      Diep BA, Carleton HA, Chang RF, et al. Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 2006; 193:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/44\">",
"      Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/45\">",
"      Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/46\">",
"      Mart&iacute;nez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004; 23:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/47\">",
"      Bocchini CE, Hulten KG, Mason EO Jr, et al. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 2006; 117:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/48\">",
"      Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007; 45:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/49\">",
"      Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/50\">",
"      Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007; 13:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/51\">",
"      Mendes RE, Deshpande LM, Castanheira M, et al. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 2008; 52:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/52\">",
"      Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/53\">",
"      Fortunov RM, Hulten KG, Hammerman WA, et al. Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates. Pediatrics 2006; 118:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/54\">",
"      Boyce JM. Increasing prevalence of methicillin-resistant Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1990; 11:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/55\">",
"      Voss A, Milatovic D, Wallrauch-Schwarz C, et al. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/56\">",
"      Heininger U, Datta F, Gervaix A, et al. Prevalence of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) in children a multicenter cross-sectional study. Pediatr Infect Dis J 2007; 26:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/57\">",
"      Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006; 12:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/58\">",
"      Raymond J, Aujard Y. Nosocomial infections in pediatric patients: a European, multicenter prospective study. European Study Group. Infect Control Hosp Epidemiol 2000; 21:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/59\">",
"      Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003; 22:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/60\">",
"      Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/61\">",
"      Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/62\">",
"      Klevens RM, Edwards JR, Gaynes RP, National Nosocomial Infections Surveillance System. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis 2008; 47:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/63\">",
"      Davis KA, Stewart JJ, Crouch HK, et al. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004; 39:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/64\">",
"      Thompson RL, Cabezudo I, Wenzel RP. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982; 97:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/65\">",
"      Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/66\">",
"      Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis 2009; 49:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/67\">",
"      Baggett HC, Hennessy TW, Leman R, et al. An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect Control Hosp Epidemiol 2003; 24:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/68\">",
"      Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/69\">",
"      Centers for Disease Control and Prevention (CDC). Methicillin-resistant staphylococcus aureus infections among competitive sports participants--Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 2003; 52:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/70\">",
"      Centers for Disease Control and Prevention (CDC). Methicillin-resistant Staphylococcus aureus among players on a high school football team--New York City, 2007. MMWR Morb Mortal Wkly Rep 2009; 58:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/71\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections--Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2003; 52:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/72\">",
"      Shahin R, Johnson IL, Jamieson F, et al. Methicillin-resistant Staphylococcus aureus carriage in a child care center following a case of disease. Toronto Child Care Center Study Group. Arch Pediatr Adolesc Med 1999; 153:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/73\">",
"      Zinderman CE, Conner B, Malakooti MA, et al. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis 2004; 10:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/74\">",
"      Aiello AE, Lowy FD, Wright LN, Larson EL. Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies. Lancet Infect Dis 2006; 6:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/75\">",
"      Lee NE, Taylor MM, Bancroft E, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005; 40:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/76\">",
"      Centers for Disease Control and Prevention (CDC). Methicillin-resistant Staphylococcus aureus infections in correctional facilities---Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003; 52:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/77\">",
"      Centers for Disease Control and Prevention (CDC). Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison--Mississippi, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/78\">",
"      Centers for Disease Control and Prevention (CDC). Methicillin-resistant Staphylococcus aureus skin infections among tattoo recipients--Ohio, Kentucky, and Vermont, 2004-2005. MMWR Morb Mortal Wkly Rep 2006; 55:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/79\">",
"      Begier EM, Frenette K, Barrett NL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis 2004; 39:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/80\">",
"      Young DM, Harris HW, Charlebois ED, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 2004; 139:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/81\">",
"      Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004; 189:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/82\">",
"      Guillemot D, Bonacorsi S, Blanchard JS, et al. Amoxicillin-clavulanate therapy increases childhood nasal colonization by methicillin-susceptible Staphylococcus aureus strains producing high levels of penicillinase. Antimicrob Agents Chemother 2004; 48:4618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/83\">",
"      Fortunov RM, Hulten KG, Allen CH, et al. Nasal Staphylococcus aureus colonization among mothers of term and late preterm previously healthy neonates with community-acquired Staphylococcus aureus infections. Pediatr Infect Dis J 2011; 30:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/84\">",
"      Leshem E, Maayan-Metzger A, Rahav G, et al. Transmission of Staphylococcus aureus from mothers to newborns. Pediatr Infect Dis J 2012; 31:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/85\">",
"      Jimenez-Truque N, Tedeschi S, Saye EJ, et al. Relationship between maternal and neonatal Staphylococcus aureus colonization. Pediatrics 2012; 129:e1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/86\">",
"      Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006; 193:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/87\">",
"      Kenner J, O'Connor T, Piantanida N, et al. Rates of carriage of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in an outpatient population. Infect Control Hosp Epidemiol 2003; 24:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/88\">",
"      Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005; 41:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/89\">",
"      Ellis MW, Hospenthal DR, Dooley DP, et al. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004; 39:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/90\">",
"      von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/91\">",
"      Milstone AM, Goldner BW, Ross T, et al. Methicillin-resistant Staphylococcus aureus colonization and risk of subsequent infection in critically ill children: importance of preventing nosocomial methicillin-resistant Staphylococcus aureus transmission. Clin Infect Dis 2011; 53:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/92\">",
"      Coello R, Jim&eacute;nez J, Garc&iacute;a M, et al. Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 990 patients. Eur J Clin Microbiol Infect Dis 1994; 13:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/93\">",
"      Cookson B, Peters B, Webster M, et al. Staff carriage of epidemic methicillin-resistant Staphylococcus aureus. J Clin Microbiol 1989; 27:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/94\">",
"      Boyce JM, Opal SM, Potter-Bynoe G, Medeiros AA. Spread of methicillin-resistant Staphylococcus aureus in a hospital after exposure to a health care worker with chronic sinusitis. Clin Infect Dis 1993; 17:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/95\">",
"      Sherertz RJ, Reagan DR, Hampton KD, et al. A cloud adult: the Staphylococcus aureus-virus interaction revisited. Ann Intern Med 1996; 124:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/96\">",
"      El Helali N, Carbonne A, Naas T, et al. Nosocomial outbreak of staphylococcal scalded skin syndrome in neonates: epidemiological investigation and control. J Hosp Infect 2005; 61:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/97\">",
"      Hoeger PH, Lenz W, Boutonnier A, Fournier JM. Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis 1992; 165:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/98\">",
"      Sanford MD, Widmer AF, Bale MJ, et al. Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1994; 19:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/99\">",
"      Reagan DR, Doebbeling BN, Pfaller MA, et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991; 114:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/100\">",
"      Cook HA, Furuya EY, Larson E, et al. Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/101\">",
"      Chen KT, Huard RC, Della-Latta P, Saiman L. Prevalence of methicillin-sensitive and methicillin-resistant Staphylococcus aureus in pregnant women. Obstet Gynecol 2006; 108:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/102\">",
"      Eveillard M, de Lassence A, Lancien E, et al. Evaluation of a strategy of screening multiple anatomical sites for methicillin-resistant Staphylococcus aureus at admission to a teaching hospital. Infect Control Hosp Epidemiol 2006; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/103\">",
"      Rosenthal A, White D, Churilla S, et al. Optimal surveillance culture sites for detection of methicillin-resistant Staphylococcus aureus in newborns. J Clin Microbiol 2006; 44:4234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/104\">",
"      Lautenbach E, Nachamkin I, Hu B, et al. Surveillance cultures for detection of methicillin-resistant Staphylococcus aureus: diagnostic yield of anatomic sites and comparison of provider- and patient-collected samples. Infect Control Hosp Epidemiol 2009; 30:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/105\">",
"      Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008; 197:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/106\">",
"      Creech CB 2nd, Kernodle DS, Alsentzer A, et al. Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J 2005; 24:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/107\">",
"      Alfaro C, Mascher-Denen M, Fergie J, Purcell K. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage in patients admitted to Driscoll Children's Hospital. Pediatr Infect Dis J 2006; 25:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/108\">",
"      Fluegge K, Adams B, Luetke Volksbeck U, et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in a southwestern region of Germany. Eur J Pediatr 2006; 165:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/109\">",
"      Fritz SA, Garbutt J, Elward A, et al. Prevalence of and risk factors for community-acquired methicillin-resistant and methicillin-sensitive staphylococcus aureus colonization in children seen in a practice-based research network. Pediatrics 2008; 121:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/110\">",
"      Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004; 363:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/111\">",
"      Regev-Yochay G, Dagan R, Raz M, et al. Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA 2004; 292:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/112\">",
"      Boyce JM, Potter-Bynoe G, Chenevert C, King T. Environmental contamination due to methicillin-resistant Staphylococcus aureus: possible infection control implications. Infect Control Hosp Epidemiol 1997; 18:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/113\">",
"      Smith MA, Mathewson JJ, Ulert IA, et al. Contaminated stethoscopes revisited. Arch Intern Med 1996; 156:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/114\">",
"      Guinto CH, Bottone EJ, Raffalli JT, et al. Evaluation of dedicated stethoscopes as a potential source of nosocomial pathogens. Am J Infect Control 2002; 30:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/115\">",
"      Merlin MA, Wong ML, Pryor PW, et al. Prevalence of methicillin-resistant Staphylococcus aureus on the stethoscopes of emergency medical services providers. Prehosp Emerg Care 2009; 13:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/116\">",
"      Coronado F, Nicholas JA, Wallace BJ, et al. Community-associated methicillin-resistant Staphylococcus aureus skin infections in a religious community. Epidemiol Infect 2007; 135:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/117\">",
"      Boyce JM. Methicillin-resistant Staphylococcus aureus. Detection, epidemiology, and control measures. Infect Dis Clin North Am 1989; 3:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/118\">",
"      National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/119\">",
"      Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/120\">",
"      Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/121\">",
"      Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007; 45 Suppl 3:S171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/122\">",
"      Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/123\">",
"      Reed SD, Friedman JY, Engemann JJ, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005; 26:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/124\">",
"      Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999; 20:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/125\">",
"      Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/126\">",
"      Boubaker K, Diebold P, Blanc DS, et al. Panton-valentine leukocidin and staphyloccoccal skin infections in schoolchildren. Emerg Infect Dis 2004; 10:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/127\">",
"      Jeyaratnam D, Reid C, Kearns A, Klein J. Community associated MRSA: an alert to paediatricians. Arch Dis Child 2006; 91:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/128\">",
"      Khairulddin N, Bishop L, Lamagni TL, et al. Emergence of methicillin resistant Staphylococcus aureus (MRSA) bacteraemia among children in England and Wales, 1990-2001. Arch Dis Child 2004; 89:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/129\">",
"      Miles F, Voss L, Segedin E, Anderson BJ. Review of Staphylococcus aureus infections requiring admission to a paediatric intensive care unit. Arch Dis Child 2005; 90:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/130\">",
"      Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005; 41:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/131\">",
"      Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics 2004; 113:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/132\">",
"      Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/133\">",
"      Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus. J Pediatr Orthop 2006; 26:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/134\">",
"      Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/135\">",
"      Schwartz KL, Nourse C. Panton-Valentine leukocidin-associated Staphylococcus aureus necrotizing pneumonia in infants: a report of four cases and review of the literature. Eur J Pediatr 2012; 171:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/136\">",
"      Hasty MB, Klasner A, Kness S, et al. Cutaneous community-associated methicillin-resistant staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments. Acad Emerg Med 2007; 14:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/137\">",
"      Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006; 43:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/138\">",
"      Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/139\">",
"      Wright CT, Stocks RM, Armstrong DL, et al. Pediatric mediastinitis as a complication of methicillin-resistant Staphylococcus aureus retropharyngeal abscess. Arch Otolaryngol Head Neck Surg 2008; 134:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/140\">",
"      McKinley SH, Yen MT, Miller AM, Yen KG. Microbiology of pediatric orbital cellulitis. Am J Ophthalmol 2007; 144:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/141\">",
"      Brook I. Recovery of methicillin resistant Staphylococcus aureus from a child with acute otitis media. Pediatr Infect Dis J 2008; 27:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/142\">",
"      Ochoa TJ, Mohr J, Wanger A, et al. Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients. Emerg Infect Dis 2005; 11:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/21/30042/abstract/143\">",
"      Bradley J, Frenck R. CA-MRSA infections an increasing concern in early infancy. AAP News 2006; 27:16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6065 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30042=[""].join("\n");
var outline_f29_21_30042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MRSA DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HA-MRSA infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hospital-onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Community-onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CA-MRSA infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MICROBIOLOGIC CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HA-MRSA strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CA-MRSA strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CO HA-MRSA strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1183236\">",
"      Linezolid resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nosocomial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CA-MRSA infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CO HA-MRSA infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Colonized individuals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Contaminated surfaces",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CLINICAL SPECTRUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nosocomial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Community infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - SSTI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Invasive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - In young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=related_link\">",
"      Epidemiology, pathogenesis, and etiology of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17416?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=related_link\">",
"      Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26792?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40758?source=related_link\">",
"      Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_21_30043="Autopsy findings in SIDS";
var content_f29_21_30043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Typical morphologic findings in a SIDS autopsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        External examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Well-developed, well-nourished baby",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frothy blood-tinged fluid around the nose (50 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanosis of the lips and nail beds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypostatic staining anteriorly suggesting face down position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Internal examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary congestion (89 versus 80 percent in controls)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary edema (63 versus 51 percent in controls)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thymic petechiae (44 versus 25 percent in controls)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent hepatic erythropoiesis (23 versus 14 percent in controls)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Subacute\" inflammation of the upper respiratory tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focal fibrinoid necrosis of the larynx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Full expansion of the lungs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liquid blood in the heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal prominent lymphoid tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Empty urinary bladder (50 percent)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30043=[""].join("\n");
var outline_f29_21_30043=null;
var title_f29_21_30044="Causes of FUO in older adults";
var content_f29_21_30044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of FUO in older adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Major causes of FUO",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intra-abdominal abscess",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberculosis",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infective endocarditis",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total",
"       </td>",
"       <td>",
"        <strong>",
"         35",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Collagen vascular disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giant cell arteritis plus polymyalgia rheumatica",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polyarteritis nodosa",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Others",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total",
"       </td>",
"       <td>",
"        <strong>",
"         28",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphoma plus other hematologic disorders",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Solid tumors (usually with liver involvement)",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total",
"       </td>",
"       <td>",
"        <strong>",
"         19",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        (eg, pulmonary emboli/venous thrombosis, drug fever)",
"       </td>",
"       <td>",
"        <strong>",
"         8",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         No diagnosis",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FUO: fever of unknown origin.",
"     <br>",
"      * Data pooled from three trials of FUO in older adults (see below).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Knockaert, et al. Fever of unknown origin in elderly patients. J Am Geriatr Soc 1993; 41:1187.",
"       </li>",
"       <li>",
"        Expositio, et al. Fever of unknown origin in the elderly. J Am Geriatr Soc 1978; 26:498.",
"       </li>",
"       <li>",
"        Barrier, et al. Les fievres prolongu&eacute;es inexpliqu&eacute;es chez les personnes ag&eacute;es. Concours Med 1982; 104:4679.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30044=[""].join("\n");
var outline_f29_21_30044=null;
var title_f29_21_30045="Disorders with cataracts";
var content_f29_21_30045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric disorders associated with cataracts",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Craniofacial syndromes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hallermann-Streiff syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Smith-Lemli-Opitz syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Apert syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Crouzon syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pierre-Robin syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Meckel-Gruber syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Metabolic disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Galactosemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypoparathyroidism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Infantile hypoglycemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Maternal diabetes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mannosiderosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fabry disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Refsum disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Zellweger syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Skeletal disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Stickler syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chrondrodysplasia punctata (Conradi syndrome)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Central nervous system disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Marinesco-Sjogren syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Walker-Warburg syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Miscellaneous",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Norrie disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Marshall syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nail-patella syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Intrauterine infection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Toxoplasmosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rubella",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytomegalovirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Herpes simplex and varicella",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Syphilis",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Dermatologic disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ectodermal dysplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Incontinentia pigmenti",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rothmund-Thomson syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Werner syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ichthyosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cockayne syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Progeria",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Renal disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lowe syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Alport syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Muscular disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Myotonic dystrophy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Walker-Warburg syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Apical syndromes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rubinstein-Taybi syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bardet-Biedl syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oculodentodigital dysplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Chromosomal anomalies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Down syndrome (Trisomy 21)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Edward syndrome (Trisomy 18)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Patau syndrome (Trisomy 13)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Wolf-Hirschhorn syndrome (4p-syndrome)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Turner syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cri du chat syndrome (5p-syndrome)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Ocular disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Retinopathy of prematurity",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Persistent Hyperplastic Primary Vitreous (PHPV)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sticklers disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Aniridia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Uveitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neurofibromatosis type 2",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30045=[""].join("\n");
var outline_f29_21_30045=null;
var title_f29_21_30046="MacConkey agar";
var content_f29_21_30046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MacConkey agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Because of the abundant normal flora present in stool, detection of enteric pathogens requires culture on selective and differential media. MacConkey agar inhibits the growth of gram-positive bacteria and differentiates between gram-negative bacteria that ferment lactose (pink to red colonies on this medium) and those that do not (colorless). Neither Salmonella nor Shigella can ferment lactose on this medium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30046=[""].join("\n");
var outline_f29_21_30046=null;
var title_f29_21_30047="Precut from pancreatic duct";
var content_f29_21_30047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Precut sphincterotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The nose of the pull-type papillotome is left in the pancreatic duct and the common channel is then unroofed in the biliary direction with the cutting wire.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas A Howell, MD and David J Desilets, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_21_30047=[""].join("\n");
var outline_f29_21_30047=null;
